1 Roche

YTD September 2013 sales

Basel, 17 October 2013

2 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others: 1 pricing and product initiatives of competitors; 2 legislative and regulatory developments and economic conditions; 3 delay or inability in obtaining regulatory approvals or bringing products to market; 4 fluctuations in currency exchange rates and general financial market conditions; 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products; 6 increased government pricing pressures; 7 interruptions in production; 8 loss of or inability to obtain adequate protection for intellectual property rights; 9 litigation; 10 loss of key executives or other employees; and 11 adverse publicity and news coverage. Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche’s earnings or earnings per share for this year or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche. For marketed products discussed in this presentation, please see full prescribing information on our website www.roche.com All mentioned trademarks are legally protected. 3 Group Severin Schwan Chief Executive Officer

4 YTD Sept 2013: Strong sales momentum continues

2013 2012 Change in % CHFbn CHFbn CHF CER

Pharmaceuticals Division 27.2 26.2 47

Diagnostics Division 7.7 7.5 24

Roche Group 34.9 33.7 36

5 CER=Constant Exchange Rates Group: Continued strong sales growth

10%

8% 8% 6% 6% 6% 6% 4% 4% 6% 4% 4% Excluding 2% 340B sales 2% reserves release 1% 0% 0% 0% -2%

-4% -3% -5% -6% Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 10 10 11 11 11 11 12 12 12 12 13 13 13

6 All values at constant exchange rates Group growth supported by all regions

20% US 15% 14%

10% 9% US excl. 340B 7% International 5% 4% Japan 3% Europe 0%

-5%

-10%

-15%

-20% Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 10 10 11 11 11 11 12 12 12 12 13 13 13

7 All values at constant exchange rates H2 2013 Highlights

Q3 2013 • HER2 franchise: – Perjeta & Herceptin: FDA approval in neo-adjuvant setting – SC Herceptin: Approved in EU – Kadcyla: CHMP positive recommendation • Etrolizumab: Decision to move to phase III • Lampalizumab: Encouraging phase II data presented • Professional Diagnostics: cobas 8100 launch

Q4 2013 expected milestones • Actemra Subcutaneous: FDA action date (PDUFA) 21 Oct • GA101: Stage II of CLL11 at ASH; FDA action date (PDUFA) 20 Dec • Lampalizumab: Phase II biomarker data to be presented at AAO

8 2013: Late-stage enabling milestones

etrolizumab Phase III decision Data readout Partnering options UC and CD pending Q4 2013 / H1 2014 lebrikizumab asthma gantenerumab1 Alzheimer’s ocrelizumab MS bitopertin mGlu2 schizophrenia treatment-resistant depression Bcl-2i (GDC 0199) mGlu5 hem. cancers treatment-resistant depression anti-PDL1 crenezumab solid tumours Alzheimer's cobimetinib (MEKi) CD22/CD79b ADC melanoma hem. cancers onartuzumab (MetMAb) anti-EGFL7 HCV DAA NSCLC solid tumours HepC obinutuzumab (GA101) alectinib (ALKi) PI3 kinase inclacumab (P selectin) CLL NSCLC solid tumours ACS/CVD Kadcyla (EU) lampalizumab dual PI3 kinase/mTOR anti-PCSK9 HER2+ BC geographic atrophy solid tumours metabolic diseases Ph III NMEs

Oncology Virology Ophthalmology Moved to phase III Neuroscience Immunology Metabolism 9 1Phase II/III label enabling 2013 Outlook

Group sales growth1 In line with sales growth recorded in 2012

Core EPS growth1 Ahead of sales growth

Dividend outlook Further increase dividend

10 1At constant exchange rates; Excluding one-off Past Service Income impact of ~CHF 200m on core net income and excluding 340B reserve release impact of CHF 184m on sales and ~CHF 100m on core net income Pharmaceuticals Division Daniel O’Day COO Roche Pharmaceuticals

11 YTD Sept 2013 sales

Innovation

Outlook

12 YTD Sept 2013: Pharma sales US and Int’l as the major growth contributor

Excl. 2013 2012 Change in % 340B CHFm CHFm CHF CER CER Pharmaceuticals Division 27,190 26,198 4 7 6 United States 11,429 10,270 11 12 10 Europe 6,952 6,715 4 2 Japan 2,492 2,966 -16 3 International 6,317 6,247 1 5

13 CER=Constant Exchange Rates YTD Sept 2013: Pharma sales Oncology, Actemra and Tamiflu main growth drivers

Avastin +13%

MabThera/Rituxan +6%

Herceptin +6%

Actemra/RoActemra +33%

Tamiflu +81%

Perjeta NM

Neorecormon/Epogin -19% US Evista -100% Europe Japan Pegasys -19% International

-400 -200 0 200 400 600

14 Absolute amounts at 2012 exchange rates; growth at CER=Constant Exchange Rates YTD Sept 2013 sales: Oncology franchise up 9%

CER growth Increased share & duration of treatment in DLBCL in MabThera/ +6% Rituxan Europe driving growth

Perjeta Herceptin volume growth driven by Asia and LatAm. HER2 Herceptin +13% Solid launch of Perjeta and Kadcyla Kadcyla Continued uptake in ovarian cancer (EU), increased use in Avastin +13% mCRC due to treatment through multiple lines label

Solid demand ahead of the exclusivity loss Xeloda +3% (EU Dec 2013, US Feb 2014)

Tarceva +5% Good uptake in 1st line EGFR mut+ NSCLC

Zelboraf +65% Fully penetrated in US, strong growth in Europe

CHFbn 0.0 2.0 4.0 6.0 15 CER=Constant Exchange Rates Oncology YTD Sept 2013 sales: CHF 16.9bn Avastin: Continued uptake in ovarian cancer and treatment through multiple lines in mCRC

CHFm 1'800 14% YoY CER growth 13% 11% 11% 8% 1% 5% -6% -9% -10% -2%

1'200

600 International Japan Europe US 0 Q1 11 Q2 11 Q3 11 Q4 11 Q1 12 Q2 12 Q3 12 Q4 12 Q1 13 Q2 13 Q3 13

16 Absolute amounts at 2012 exchange rates; growth at CER=Constant Exchange Rates Q3 highlights in HER2 franchise

• Strong US uptake in HER2+ mBC 2line and beyond • TH3RESA: Kadcyla superior vs. Physicians choice (80% Herceptin) • Positive opinion in Europe

• Encouraging rollout in Europe • US approval of neo-adjuvant HER2+ BC

• Approval in Europe; launched in some major EU countries already

17 Lucentis: Solid growth

Lucentis quarterly sales (USDm) 500 AMD • Benefit from label change in AMD

400 Eylea wAMD AMD DME and RVO Less-frequent than monthly dosing • Further increase in patient share 300 Lucentis DME

200 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 10 10 10 10 11 11 11 11 12 12 12 12 13 13 13

18 AMD=wet age-related macular degeneration; RVO=retinal vein occlusion; DME=diabetic macular edema Actemra/RoActemra: Solid growth in all regions

Quarterly sales Subcutaneous (SC)

300 CHFm +33% +33% 250 +30% +32% +27% 200

150 RA global market

100 IV 50 ~30% ~70%

0 Subcutaneous Q3 12 Q4 12 Q1 13 Q2 13 Q3 13 US Europe Japan International

SC formulation FDA action date (PDUFA) 21 Oct 2013 19 Growth at CER=Constant Exchange Rates E7 Pharma sales: Emerging markets remain strong

CHFm 1'200 H1 13 H2 12 +11% +9% YoY CER growth H1 12 +15% +13% 1'000 -3% Korea -28% Russia 800 -14% Mexico +4% Turkey +161% India 600

+16% China 400

200 +28% Brazil

0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2012 2013

20 CER=Constant Exchange Rates YTD Sept 2013 sales

Innovation

Outlook

21 HER2+ BC: US approval of Perjeta & Herceptin in neoadjuvant setting

Association of pCR with event-free survival (EFS) in HER2-positive BC Perjeta in neo-adjuvant setting (NEOSPHERE) p = 0.0141

45.8%

29.0% 24.0%

16.8% pathological complete response

Herceptin + Herceptin Herceptin Perjeta docetaxel & Perjeta & Perjeta + docetaxel + docetaxel

CTNeoBC Meta-analysis, FDA 22 Etrolizumab: Decision to start phase III Ulcerative colitis and Crohn’s disease

Best-in-disease in Inflammatory Bowel Disease >3000 patients program

Ulcerative colitis Crohn’s disease

• First subcutaneous gut-selective anti-integrin • Better safety profile with reduced risk of severe infection or malignancy • PHC through αE expression as potential companion diagnostics • Further details after discussions with healthcare authorities

FPI H1 2014. Expect first data 2018

23 Lampalizumab: Encouraging phase II data in Geographic Atrophy

Advanced AMD Early AMD Intermediate AMD Wet AMD

Initially, visual acuity minimally affected; signs are anatomic (drusen and pigmentary changes) with symptoms of visual function impairment (e.g, dark adaptation, contrast sensitivity)

Geographic Atrophy High efficacy in subpopulation with non fovea- fovea- fovea- exploratory biomarker threatening threatening involved • GA progression rate decreased by 44% at 18 months • All comers: 20.4 % reduction rate at 18 months

24 YTD Sept 2013 results

Innovation

Outlook

25 2013: Late-stage enabling milestones

etrolizumab Phase III decision Data readout Partnering options UC and CD pending Q4 2013 / H1 2014 lebrikizumab asthma gantenerumab1 Alzheimer’s ocrelizumab MS bitopertin mGlu2 schizophrenia treatment-resistant depression Bcl-2i (GDC 0199) mGlu5 hem. cancers treatment-resistant depression anti-PDL1 crenezumab solid tumours Alzheimer's cobimetinib (MEKi) CD22/CD79b ADC melanoma hem. cancers onartuzumab (MetMAb) anti-EGFL7 HCV DAA NSCLC solid tumours HepC obinutuzumab (GA101) alectinib (ALKi) PI3 kinase inclacumab (P selectin) CLL NSCLC solid tumours ACS/CVD Kadcyla (EU) lampalizumab dual PI3 kinase/mTOR anti-PCSK9 HER2+ BC geographic atrophy solid tumours metabolic diseases Ph III NMEs

Oncology Virology Ophthalmology Moved to phase III Neuroscience Immunology Metabolism 26 1Phase II/III label enabling Planned data presentations in Q4 2013

ASH

New Orleans, 16-19 Nov New Orleans, 7-10 Dec

lampalizumab obinutuzumab (GA101) (anti-factor D) CLL11 stage II Phase II biomarker data rituximab vs. GA101

27 2013: Major clinical and regulatory news flow

Compound Indication Milestone Avastin mCRC (TML) US EU approval Avastin Newly diagnosed glioblastoma EU filing  Actemra subcutaneous RA US approval Erivedge Advanced BCC EU approval  Herceptin subcutaneous HER2-positive BC EU approval  Regulatory Lucentis wAMD (HARBOR) US approval  Perjeta 1st line HER2-positive mBC EU approval  Perjeta Neoadjuvant HER2+ BC US filing  US approval  Tarceva EGFR mut+ 1st line NSCLC US approval Kadcyla 2nd line HER2-positive mBC US EU approval obinutuzumab (GA101) Front line CLL US approval aleglitazar Metabolic diseases Ph III  obinutuzumab (GA101) Front line CLL Ph III  Phase III Tarceva Adjuvant NSCLC Ph III RADIANT Xolair Chronic idiopathic urticaria Ph III  US filing  Milestones previously expected later than 2013 28 Outcome studies are event driven, timelines may change Diagnostics Division Roland Diggelmann

COO Roche Diagnostics Picture

29 YTD Sept 2013: Diagnostics sales Growth driven by Professional Diagnostics

2013 2012 change in % CHF m CHF m CHF CER Diagnostics Division 7,677 7,496 +2 +4 Professional Diagnostics1 4,227 4,010 +5 +7 Diabetes Care 1,781 1,837 -3 -2 Molecular Diagnostics1 1,188 1,191 0 +2 Tissue Diagnostics 481 458 +5 +6

CER=Constant Exchange Rates; 30 12012 sales restated for Applied Science integration into Professional Diagnostics and Molecular Diagnostics YTD Sept 2013: Diagnostics sales Growth driven by Asia Pacific and Latin America

CHF 7,677m CER sales growth

1,912 North America 25% Diagnostics Division 4%

Latin America 8% North 0% 576 America

EMEA* 3%

1,267 Asia Pacific 16% Latin America 12% 3,564 Asia 358 Japan 5% Pacific 12% EMEA* 46% Japan 1%

31 CER=Constant Exchange Rates; * Europe, Middle East, Africa YTD Sept 2013: Diagnostics highlights

CER growth

Strong sales growth in immunoassays (13%), coagulation self Professional Dia +7% monitoring (7%) and workflow automation (23%); launch of lab automation system cobas 8100

Diabetes Care -2% Strong sales growth from new products and ongoing restructuring initiatives

Sales growth driven by HPV (101%), oncology (46%) and +2% Molecular Dia qPCR for life sciences (7%)

Growth driven by IHC1 tests; double digit growth in Europe Tissue Dia +6% EMEA and emerging markets North America RoW CHFbn 012345

32 CER=Constant Exchange Rates; EMEA=Europe, Middle East and Africa; 1 Immunohistochemistry Professional Diagnostics Launch of cobas 8100

Automated workflow series for labs • Integrated pre and post analytics • Connectivity and flexible workflow • High throughput and small footprint • Increasing testing efficiency

CE mark in Q3 2013

Integrated cobas 8100 • Launched in all major EU countries, Singapore, Australia, and Canada.

33 Professional Diagnostics Immunoassays: Main driver of sales growth

YTD Sept: CHF 1.9bn immunoassay sales (+13%)

YoY 14% 12% CER growth 12% 7% 22%

10%

7% 42% 16% Sales

Tumour Thyroid Cardiac Other Women's Infectious Anemia Critical Hormones markers health diseases Care 34 CER=Constant Exchange Rates; “Other” include mainly instruments and accessories Molecular Diagnostics Strong sales growth from HPV

Increasing share in US market cobas HPV Test • Over 200 cobas 4800 systems placed

Three results in one test • YTD sales more than doubled

12 high risk HPV pool FDA filing for primary screening HPV Genotype 16 • 3 year data from ATHENA to expand label HPV Genotype 18 for primary screening of cervical cancer • Received acceptance of submission

Ongoing pilot studies in Europe • Sweden, Netherlands, UK and Italy

35 Sequencing: Partnership with Pacific Biosciences

• Building on single molecule real time technology • Collaboration agreement: – Pac Bio responsible for development and manufacturing of new sequencing systems intended for clinical use – Roche undertakes product specifications, regulatory work and exclusive worldwide distribution in clinical diagnostics market

36 Key launches 2013

Area Product Market BA1 Labs cobas 8100 – Next generation modular pre-analytics EU RPD

Life Software for long read Instruments GS FLX+ long amplicons- WW RMD Sciences targeted sequencing  / Devices Diabetes Accu-Chek Insight- Next generation insulin pump & EU RDC Care bGM2 system Accu-Chek Active LCM- Next-generation bGM2 meter EU  RDC with maltose independent test strips Oncology Calcitonin – Medullary thyroid cancer EU  RPD proGRP- Small cell lung cancer EU  RPD CINtec PLUS Cytology- Cervical pre-cancer EU RTD ER- Breast cancer US  RTD Tests/ EGFR- Lung cancer US  RMD Assays Infectious MPX 2.0 – Next generation blood screening multiplex test US RMD Diseases for HIV, HCV & HBV CAP/CTM HCV 2.0 – Next generation HCV viral load test US  RMD Transplant immunosuppressive drug Cyclosporin, Tacrolimus – EU RPD monitoring  Sequencing Targeted next gen. SeqCap EZ Reagent Kits - WW RMD sequencing 

1 Business Areas. RPD: Roche Professional Diagnostics; RDC: Roche Diabetes Care; RMD: Roche Molecular Diagnostics, 37 RTD: Roche Tissue Diagnostics; 2 blood glucose monitoring Finance Alan Hippe Chief Financial Officer

38 340B reserve release: One-off effect in Q3 2013

Reserve released: • Rituxan ~55% Sales CHF +184m • Herceptin ~20% Net income ~CHF +100m • Avastin ~15%

Reserves for 340B rebates for orphan and non-orphan indications

Aug July 1 Oct 2010 2013 2013

HRSA1 final ruling: 340B rebates US healthcare 340B rebates effective as for non-orphan reform of 1 Oct 2013 indications

39 1 Health Resources and Services Administration; 340B Drug Discount Program is a U.S federal government program that requires drug manufacturers to provide outpatient drugs to eligible health care organizations/covered entities at significantly reduced prices Investment in manufacturing network Ensure supply and meet pipeline requirements

Bacterial cell culture CHF 350m Penzberg

Vacaville Basel Antibody-drug Oceanside conjugates CHF 190m Mammalian cell culture CHF 260m

Total investment: CHF 800m over next 5 years Reactivation of Vacaville plant: write-back of ~CHF 500m one-off non-core income 40 Negative exchange rate impact on sales growth in Q3 due to JPY and USD

Average exchange rates versus prior year period CHF / EUR +1.6% +2.4% +2.6% CHF / USD +0.9% +0.7% -3.1% CHF / JPY -13.3% -18.2% -23.0%

Difference in CHF / CER -0.8 %p -1.4 %p -5.4%p growth 8.1%

5.9% 5.1% Sales 4.1% growth CER CHF 2.7% 2.7% 2013 growth growth vs. 2012

Q1 Q2 Q3 Q4 41 CER=Constant Exchange Rates Currency impact on Swiss Franc results 2013 Moderate currency impact expected

CHF / USD Assumed average YTD 2013 Average YTD 2012 0.94 0.94 0.93 0.94 -1% -1% +1% Assuming the 30 Sept 2013 exchange +1% 0.93 0.93 0.93 0.92 rates remain stable until end of 2013,

0.910.91 0.91 2013 impact is expected to be (%p): 0.92 0.920.95 0.94 0.960.93 0.95 0.93 0.92 Monthly avg fx rates Fx rate at 30 September Q1 HY Sep FY 2013 2013 JFMAMJJASOND YTD

CHF / EUR Sales -1 -1 -3 -3 Core 1.23 1.23 1.23 1.23 operating -1 -3 profit +2% +2% +2% +2% Core EPS -2 -4 1.21 1.20 1.20 1.21

1.23 1.23 1.23 1.22 1.24 1.23 1.24 1.23 1.23 1.23 1.23 1.23

JFMAMJJASOND 42 2013 Outlook

Group sales growth1 In line with sales growth recorded in 2012

Core EPS growth1 Ahead of sales growth

Dividend outlook Further increase dividend

43 1At constant exchange rates; Excluding one-off Past Service Income impact of ~CHF 200m on core net income and excluding 340B reserve release impact of CHF 184m on sales and ~CHF 100m on core net income Doing now what patients need next

44 Roche Group development pipeline

Marketed products development programmes

Roche Pharma global development programmes

Roche Pharma research and early development

Genentech research and early development

Roche Group YTD Sept 2013 sales

Diagnostics

Foreign exchange rate information 45 Changes to the development pipeline Q3 2013 update

New to Phase I New to Phase II New to Phase III New to Registration

1 NME 2 NMEs 2 AIs submissions in EU RG7863 TLR7 agonist (2) HBV RG7440 ipatasertib (AKT inhibitor) RG435 Avastin rel. ovarian ca. Pt- 1 AI solid tumors resistant RG3638 onartuzumab liver cancer RG7314 V1 receptor antag autism RG1569 Actemra early RA 1 AI 1 AI submission to FDA RG3616 Erivedge acute RG3648 Xolair chronic idiopathic myelogenous leukemia urticaria

Removed from Phase I Removed from Phase II Removed from Phase III Removed from Registration

3 NMEs 1 NME 1 AI following publication of 1 AI EU approval RG7129 BACE1 inh Alzheimer’s RG7414 parsatuzumab (EGFL7 results at ECC 2013 RG597 Herceptin HER2+ BC sc RG7420 MEK inh solid tumors MAb) solid tumors RG3502 Kadcyla HER2+mBC 3rd formulation WT-1 peptide cancer vaccine line 1 AI US approval (removed by Chugai) RG1273 Perjeta HER2+ BC neoadjuvant

46 Status as of September 30, 2013 Roche Group development pipeline

Phase I (31 NMEs + 6 AIs)

Oncology Other disease areas

RG3638 onartuzumab liver cancer HCC RG7624 IL-17 MAb autoimmune diseases RG7116 HER3 MAb solid tumors CHU IL-6R MAb RA RG7155 CSF-1R MAb solid tumors CHU IL-31R MAb atopic dermatitis RG7167 MEK inh solid tumors RG7745 - infectious diseases RG7212 Tweak MAb oncology RG7795 TLR7 agonist HBV RG7221 Ang2-VEGF MAb oncology RG7863 TLR7 agonist (2) HBV RG7304 Raf & MEK dual inh solid tumors RG7410 - metabolic diseases RG7356 CD44 MAb solid tumors RG7697 GIP/GLP-1 dual ago type 2 diabetes RG7388 MDM2 ant solid & hem tumors RG1662 GABRA5 NAM cognitive disorders RG7446 PD-L1 MAb+Zelboraf m. melanoma RG7203 PDE10A inh schizophrenia RG7446 PD-L1 MAb+Avastin solid tumors RG3645 Lucentis sust. deliv. AMD/RVO/DME RG7446 PD-L1 MAb solid tumors FIXaCHU /FX FIXa /FX bispecific MAb hemophilia A RG7450 Steap 1 ADC prostate ca. RG7458 MUC16 ADC ovarian ca. ADCRG7598 ADC multiple myeloma New Molecular Entity (NME) ADCRG7599 NaPi2b ADC oncology Additional Indication (AI) ADCRG7600 ADC oncology Oncology RG7601 Bcl-2 inh heme indications Immunology RG7602 ChK1 inh solid tum & lymphoma Infectious Diseases RG7604 PI3K inh solid tumors CardioMetabolism Neuroscience RG7636 ETBR ADC metastatic melanoma Ophthalmology RG7666 PI3k inh glioblastoma 2L Others RG7741 ChK1 inh(2) solid tum & lymphoma RG7842 - solid tumors RG-No Roche Genentech managed CHU Chugai managed CHU PI3K inh solid tumors 47 Status as of September 30, 2013 Roche Group development pipeline Phase II Phase III Registration (26 NMEs + 11 Als) (6 NMEs + 20 Als) (2 NMEs + 6 Als)

RG1273 Perjeta HER2+ mBC 2nd line RG435 Avastin HER2+ BC adj RG1052 MabThera NHL sc formulation RG3502 Kadcyla (T-DM1) HER2+ gastric cancer RG435 Avastin HER2-neg. BC adj RG4353 Avastin rel. ovarian ca. Pt-resistant RG3616 Erivedge AML RG435 Avastin NSCLC adj RG4353 Avastin glioblastoma 1st line RG3616 Erivedge operable BCC RG435 Avastin high risk carcinoid RG35024 Kadcyla HER2+ pretreat. mBC RG3638 onartuzumab mCRC 1st line RG4351 Avastin ovarian cancer 1st line RG7159 obinutuzumab (GA101) CLL RG3638 onartuzumab NSCLC non squamous 1st l RG4351 Avastin rel. ovarian ca. Pt-sensitive RG15693 Actemra early RA RG3638 onartuzumab NSCLC squamous 1st line RG1273 Perjeta HER2+ early BC RG1569 Actemra RA sc formulation RG3638 onartuzumab glioblastoma 2nd line RG1273 Perjeta HER2+ gastric cancer RG36485 Xolair chronic idiopathic urticaria RG7204 Zelboraf papillary thyroid cancer RG1415 Tarceva NSCLC adj pictilisibRG7321 pictilisib (PI3K inh) solid tumors RG3502 Kadcyla HER2+ mBC 1st line RG7422 apitolisib (PI3K/mTOR) solid&hem tumors RG3502 Kadcyla HER2+ early BC RG7440 ipatasertib (AKT inh) solid tumors RG3638 onartuzumab NSCLC 2nd/3rd line RG7446 PD-L1 MAb NSCLC 2nd/3rd line RG3638 onartuzumab gastric cancer RG7593 pinatuzumab vedotin (CD22 ADC) hem tumors RG7159 obinutuzumab (GA101) DLBCL 1 US only: ongoing evaluation for FDA submission 2 Submitted in EU RG7596 polatuzumab vedotin (CD79bADC) hem tumors RG7159 obinutuzumab (GA101) iNHL relapsed 3 Submitted in EU, US filing pending RG7597 HER3/EGFR MAb m. epithelial tumors RG7159 obinutuzumab (GA101) iNHL front-line 4 Approved in US, submitted in EU RG7601 Bcl-2 inh CLL rel/refract 17pdel RG7204 Zelboraf m. melanoma adj 5 Submitted in US RG7853 alectinib (ALK inhibitor) NSCLC RG7421 cobimetinib combo Zelboraf m. melanoma RG7686 glypican-3 MAb liver cancer RG1569 Actemra giant cell arteritis RG1569 Actemra systemic sclerosis RG3637 lebrikizumab severe asthma RG7413 etrolizumab ulcerative colitis RG3806 oral octreotide acromegaly RG7415 rontalizumab systemic lupus erythem CHU Suvenyl enthesopathy RG7449 quilizumab asthma RG1594 ocrelizumab RMS RG7128 mericitabine HCV RG1594 ocrelizumab PPMS New Molecular Entity (NME) RG7227 danoprevir HCV RG1678 bitopertin schiz neg symptoms Additional Indication (AI) RG7667 -CMV RG1678 bitopertin schiz subopt control RG7790 setrobuvir HCV Oncology RG1512 inclacumab ACS/CVD Immunology RG7652 PCSK9 MAb metabolic diseases Infectious Diseases CardioMetabolism RG1450 gantenerumab Alzheimer’s Neuroscience RG1577 MAO-B inh Alzheimer’s Ophthalmology RG1578 mGlu2 NAM depression RG1678 bitopertin obsessive compulsive dis. RG-No Roche Genentech managed RG7090 mGlu5 NAM tx.resistant depression CHU Chugai managed RG105 MabThera is branded as RG7314 V1 receptor antag autism Rituxan in US and Japan RG7412 crenezumab Alzheimer’s RG1569 Actemra is branded as RG7417 lampalizumab (factor D) geo. atrophy RoActemra in EU

Status as of September 30, 2013 NME submissions and their additional indications Projects currently in phase 2 and 3

ipatasertib AKTi (RG7440) solid tumors

pictilisib PI3Ki onartuzumab (MetMAb) (RG7321) solid tumors gastric cancer & other AIs

apitolisib PI3K/mTORi obinutuzumab (GA101) bitopertin (RG1678) (RG7422) solid & hem tumors Frontline NHL obsessive compulsive dis.

PD-L1 MAb (RG7446) obinutuzumab (GA101) V1 receptor antag (RG7314) NSCLC 2nd/3rd line DLBCL autism

pinatuzumab vedotin, RG7593 lebrikizumab (RG3637) gantenerumab (RG1450) CD22 ADC heme tumors asthma Alzheimer‘s

polatuzumab vedotin, RG7596 etrolizumab (RG7413) MAO-B inh (RG1577) CD79b ADC heme tumors ulcerative colitis Alzheimer‘s

HER3/EGFR MAb (RG7597) quilizumab (RG7449) mGlu2 NAM (RG1578) m. epithelial tumors asthma depression

onartuzumab (MetMAb) obinutuzumab (GA101) Bcl-2 inh (RG7601) mericitabine (RG7128) mGlu5 NAM (RG7090) mNSCLC, 2nd/3rd line iNHL relapsed CLL and NHL HCV depression

cobimetinib MEKi ocrelizumab (RG1594) glypican-3 MAb (RG7686) danoprevir*(RG7227) crenezumab (RG7412) (RG7421) combo Zelboraf PPMS and RMS liver cancer HCV Alzheimer‘s met melanoma

obinutuzumab (GA101) oral octreotide (RG3806) bitopertin (RG1678) alectinib ALKi (RG7667) lampalizumab anti-factor D CLL  acromegaly schizophrenia# (RG7853) NSCLC CMV (RG7417) geo atrophy 2013 2014 2015 2016 and beyond

Unless stated otherwise, submissions are planned to occur in US and EU Oncology Neuroscience * lead market China Immunology Ophthalmology  indicates a submission which has occurred with regulatory action pending Infectious Diseases NME # negative symptoms and sub-optimal control CardioMetabolism 49 Status as of September 30, 2013 Submissions of additional indications for existing products Projects currently in phase 2 and 3

Avastin NSCLC adj

Perjeta HER2-pos EBC *Avastin (EU)  Perjeta rel. ovarian ca. Pt-resist HER2-pos mBC 2ndline

**Avastin (US) Perjeta rel. ovarian ca. Pt-sens HER2-pos. gastric cancer

**Avastin (US) Kadcyla (T-DM1) ovarian cancer 1st line HER2-pos early BC *Avastin (EU)  Zelboraf glioblastoma 1st line met melanoma adj.

Perjeta (US)  Avastin Avastin Zelboraf HER2-pos BC neoadjuvant cervical cancer HER2-neg BC adj papillary thyroid cancer *Actemra (EU)  Avastin Kadcyla Actemra onartuzumab early RA HER2-pos BC adj HER2-pos mBC 1st line giant cell arteritis NSCLC 1L EGFR mut+ Xolair (US)  Tarceva Kadcyla Actemra Erivedge chronic idiopathic urticaria NSCLC adj HER2-pos gastric cancer systemic sclerosis AML 2013 2014 2015 2016 and beyond

 indicates submission to Health Authorities has occurred. * US filing pending Oncology Neuroscience Immunology Ophthalmology ** Approved in EU Infectious diseases Unless stated otherwise, submissions are planned to occur in US and EU. CardioMetabolism 50 Status as of September 30, 2013 Major granted and pending approvals 2013

Approved Pending approvals

Tarceva NSCLC EGFR mut+ 1st line May 2013

Perjeta HER2-pos BC neoadjuvant September 2013

Avastin Xolair mCRC TML chronic idiopathic urticaria January 2013 Filed July 2013

Kadcyla Actemra Lucentis obinutuzumab Actemra US HER2-pos pretreated mBC polyarticular JIA AMD 0.5 mg PRN CLL RA sc formulation February 2013 April 2013 February 2013 Filed Apr 2013 Filed Dec 2012

Perjeta MabThera Kadcyla Actemra HER2-pos mBC 1st line ANCA associated vasculitis HER2-pos advanced mBC RA sc formulation EU March 2013 April 2013 Filed Aug 2012 Filed Dec 2012 Erivedge Actemra obinutuzumab Actemra adv. basal cell carcinoma polyarticularJIA CLL early RA July 2013 May 2013 Filed Apr 2013 Filed June 2013

Herceptin Avastin Her2-pos BC sc formulation glioblastoma 1st line September 2013 Filed Mar 2013

Avastin rel. ovarian ca. Pt-resist Filed September 2013

MabThera NHL sc formulation Filed Dec 2012 Oncology Neuroscience Immunology Ophthalmology Infectious Diseases NME CardioMetabolism 51 Status as of September 30, 2013 Major Chugai granted and pending approvals 2013

Approved Pending approvals

Avastin Actemra Boniva/Bonviva iv. Avastin malignant glioma sc formulation osteoporosis ovarian cancer June 2013 March 2013 June 2013 Filed October 2012

Tarceva alectinib NSCLC EGFR mut 1st line ALK-pos rec/adv NSCLC June 2013 Filed October 2013

Perjeta HER2-pos mBC June 2013

Kadcyla HER2-pos mBC September 2013

Oncology Neuroscience Immunology Ophthalmology Infectious Diseases NME CardioMetabolism 52 Status as of September 30, 2013 Doing now what patients need next

53 Roche Group development pipeline

Marketed products development programmes

Roche Pharma global development programmes

Roche Pharma research and early development

Genentech research and early development

Roche Group YTD Sept 2013 sales

Diagnostics

Foreign exchange rate information 54 MabThera/Rituxan Oncology development programme

Patient Front-line follicular non-Hodgkin’s lymphoma Previously untreated chronic lymphocytic leukemia population Phase III Phase Ib SABRINA SAWYER Phase/study Subcutaneous study Subcutaneous study Study being conducted ex-US Study being conducted ex-US # of patients N=405 N=225 Design • ARM A: MabThera iv plus chemotherapy (CHOP or CVP) • Two-stage design: • ARM B: MabThera 1400mg SC plus chemotherapy - Stage 1 (dose-finding, N=55) (CHOP or CVP) Two-stage design: - Stage 2 (N=170): CLL dose confirmation: o Stage 1 (dose confirmation, N=127): PK primary • ARM A: MabThera iv plus chemotherapy endpoint (fludarabine and cyclophosphamide) o Stage 2 (N=280): Efficacy primary endpoint (ORR) • ARM B: MabThera 1600mg sc plus chemotherapy Responders will continue on maintenance every 8 weeks (fludarabine and cyclophosphamide) over 24 months

Primary • Pharmacokinetics, safety and efficacy • Part 1: PK (dose selection) endpoint • Part 2: PK of MabThera iv versus MabThera sc (arm A vs arm B) Status • Stage 1 primary endpoint (PK noninferiority) met • FPI (stage 2) Q3 2012 • Presented at ASH 2012 • Stage 1 data presented at ASH 2012 • Filed with EMA Q4 2012

Subcutaneous MabThera: applies Enhanze technology, partnered with Halozyme 55 CHOP=Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone; CVP=Cyclophosphamide, Vincristine and Prednisolone ASH=American Society of Hematology. Avastin Ovarian cancer clinical development programme

Patient Front-line metastatic population ovarian cancer Phase III Phase III Phase/study GOG-0218 ICON7

# of patients N=1,873 N=1,528

Design • ARM A: Paclitaxel and carboplatin for 6 cycles plus 5 • ARM A: Paclitaxel and carboplatin for 6 cycles cycles of concurrent placebo followed by placebo alone • ARM B: Paclitaxel and carboplatin plus concurrent for up to 22 cycles (15 months) Avastin for 6 cycles followed by Avastin alone for up to 18 • ARM B: Paclitaxel and carboplatin for 6 cycles plus 5 cycles (12 months) cycles of concurrent Avastin followed by placebo alone for up to 22 cycles (15 months) • ARM C: Paclitaxel and carboplatin for 6 cycles plus 5 cycles of concurrent Avastin followed by Avastin alone for up to 22 cycles (15 months) Avastin • 15 mg/kg q3 weeks • 7.5 mg/kg q3 weeks dose Primary • Progression-free survival • Progression-free survival endpoint Status • Study met its primary endpoint in Q1 2010 • Study met its primary endpoint Q3 2010 • Data presented at ASCO 2010 and 2011 • Data presented at ESMO 2010 and ASCO 2011 • Results: NEJM 2011 Dec 29;365(26):2484-96 • Results: NEJM 2011 Dec 29;365(26):2473-83 • OS data presented at ECC 2013 • EMA approval Q4 2011 • Re-evaluate FDA submission when final overall survival results from all phase III trials are available (expected 2013) 56 ASCO=American Society of Clinical Oncology; ESMO=European Society for Medical Oncology; ECC=European Cancer Congress NEJM=New England Journal of Medicine Avastin Ovarian cancer clinical development programme

Patient Relapsed Platinum-sensitive Relapsed Platinum-resistant population ovarian cancer ovarian cancer Phase III Phase III Phase/study OCEANS AURELIA # of patients N=484 N=361 Design • ARM A: Carboplatin, gemcitabine, and • ARM A: Paclitaxel, topotecan or liposomal concurrent placebo for 6-10 cycles, followed by doxorubicin placebo alone until disease progression • ARM B: Paclitaxel, topotecan or liposomal • ARM B: Carboplatin, gemcitabine, and doxorubicin plus Avastin concurrent Avastin for 6-10 cycles, followed by Avastin alone until disease progression.

Avastin dose • 15 mg/kg q3 weeks • 10 mg/kg q2 weeks or 15 mg/kg q3 weeks

Primary • Progression-free survival • Progression-free survival endpoint

Status • Study met its primary endpoint Q1 2011 • Study met its primary endpoint Q2 2012 • Data presented at ASCO 2011 • Data presented at ASCO 2012 • EMA approval received Q4 2012 • Filed in EU Q3 2013 • Re-evaluate FDA submission when final overall • OS data presented at ECC 2013 survival results from all phase III trials are available (expected 2013)

57 ASCO=American Society of Clinical Oncology; ECC=European Cancer Congress Avastin Cervical cancer clinical development programme

Patient Stage IVB, recurrent or persistent cervical cancer population Phase III Phase/study GOG-240 # of patients N=452 Design • ARM A: Paclitaxel, cisplatin • ARM B: Paclitaxel, cisplatin plus Avastin • ARM C: Paclitaxel, topotecan • ARM D: Paclitaxel, topotecan plus Avastin

Avastin dose • 15 mg/kg q3 weeks

Primary • Progression-free survival endpoint Status • Study met its primary endpoint Q1 2013 • Data presented at ASCO 2013 • To be filed globally 2014

58 ASCO=American Society of Clinical Oncology Avastin High risk carcinoid, brain and breast cancer development programmes

Patient First-line HER2-negative High risk carcinoid Newly diagnosed glioblastoma population metastatic breast cancer Phase III Phase III Phase III Phase/study SWOG SO518 AVAglio MERiDiAN

# of patients N=424 N=920 N=480

Design • ARM A: Depot octreotide plus • ARM A: Concurrent radiation and • ARM A: Paclitaxel + Avastin interferon alpha temozolomide plus placebo; followed by • ARM B: Paclitaxel + Placebo • ARM B: Depot octreotide plus maintenance TMZ plus placebo for 6 cycles; Avastin then placebo until disease progression • ARM B: Concurrent radiation and TMZ plus Avastin; followed by maintenance TMZ plus Avastin for 6 cycles; then Avastin (15mg/kg q3 weeks) monotherapy until disease progression Avastin dose • 15 mg/kg q3 weeks • 10 mg/kg q2 weeks or 15 mg/kg q3 weeks • 10 mg/kg q2 weeks

Primary • Progression-free survival • Progression-free survival • PFS in ITT endpoint • Overall survival • PFS in patients with high plasma VEGF-A Status • Recruitment completed • Co-primary endpoint of PFS met Q3 2012 • FPI Q3 2012 • Expect data 2013/2014 • Overall survival data presented at ASCO 2013 • Filed in EU Q1 2013

59 TMZ=temozolomide; ASCO=American Society of Clinical Oncology Avastin Adjuvant clinical development programme

Patient Adjuvant Adjuvant population lung cancer breast cancer Phase III Phase III Phase III Phase/study ECOG 5103 BETH ECOG 1505 HER2-negative HER2-positive

# of patients N=1,500 N=4,950 N=3,600

Design • ARM A: Cisplatin plus vinorelbine, • ARM A: Anthracycline plus • COHORT 1: Docetaxel/ carboplatin docetaxel, gemcitabine or pemetrexed cyclophosphamide (AC) followed by plus Herceptin ± Avastin • ARM B: Cisplatin plus vinorelbine, paclitaxel • COHORT 2: Docetaxel plus Herceptin docetaxel, gemcitabine or pemetrexed • ARM B: AC plus Avastin followed by ± Avastin, followed by 5-fluorouracil, plus Avastin up to 12 months paclitaxel plus Avastin epirubicin, cyclophosphamide • ARM C: AC plus Avastin followed by paclitaxel plus Avastin, followed by For both cohorts, patients receive Avastin up to 12 months Herceptin ± Avastin to complete one year of targeted therapy Avastin • 15 mg/kg q3 weeks • 15 mg/kg q3 weeks • 15 mg/kg q3 weeks dose Primary • Overall survival • Disease-free survival • Disease-free survival endpoint Status • FPI Q3 2007 • Enrolment completed Q2 2011 • Enrolment completed Q4 2010 • Recruitment ongoing • Expect data 2014 • Expect data 2013 • Expect data 2016

60 Herceptin Standard of care for HER2-positive early breast cancer

Patient Early-stage HER2-positive population breast cancer

Phase III Phase/study HANNAH Subcutaneous study

# of patients N=595

Design • ARM A: Chemotherapy* concurrent with Herceptin 600mg SC q3w for the first 8 cycles • ARM B: Chemotherapy* concurrent with Herceptin iv for the first 8 cycles *Chemotherapy = docetaxel then 5-FU, epirubicin, and cyclophosphamide

Primary • Serum concentration endpoint • Pathologic complete response Status • Data presented at EBCC 2012 • Filed in EU Q1 2012 • EU approval received Q3 2013

Subcutaneous Herceptin: applies Enhanze technology, partnered with Halozyme 61 EBCC=European Breast Cancer Conference Perjeta First in a new class of HER dimerization inhibitors

Patient Adjuvant HER2-positive breast Neoadjuvant HER2-positive breast cancer population cancer Phase II Phase II Phase III Phase/ study NEOSPHERE TRYPHAENA APHINITY # of patients N=417 N=225 N=4,800 Design • ARM A: Herceptin plus docetaxel • ARM A: FEC followed by Taxane • ARM A: Perjeta (840mg loading, • ARM B: Perjeta (840mg loading, with Herceptin and pertuzumab 420 q3w) plus Herceptin for 52 420mg q3w) plus Herceptin and (H+P given concurrently) weeks plus chemotherapy (6-8 docetaxel • ARM B: FEC followed by Taxane cycles) • ARM C: Perjeta plus Herceptin with Herceptin + pertuzumab • ARM B: Placebo plus Herceptin • ARM D: Perjeta plus docetaxel (H+P given sequentially) (52 weeks) plus chemotherapy (6- • ARM C: TCH + pertuzumab (H+P 8 cycles) given concurrently) Primary • Pathologic complete response •Safety • Invasive disease-free survival endpoint (pCR) (IDFS) Status • Positive data presented at SABCS • Positive safety and efficacy data • Recruitment completed Q3 2013 2010 presented at SABCS 2011 • Biomarker data presented SABCS 2011 • Filed in US Q2 2013 • FDA approval granted Q3 2013 • EU submission under evaluation

62 FEC=Fluorouracil, Epirubicin, and Cyclophosphamide; TCH=Docetaxel, Carboplatin, Herceptin; SABCS=San Antonio Breast Cancer Symposium. Perjeta First in a new class of HER dimerization inhibitors

Patient Second-line HER2-positive Advanced HER2-positive Advanced HER2-positive population metastatic breast cancer gastric cancer gastric cancer

Phase II Phase IIa Phase III Phase/ study PHEREXA JOSHUA JACOB

# of patients N=450 N=30 N=780

Design • ARM A: Herceptin plus • ARM A: Perjeta (840mg • ARM A: Perjeta (840mg Xeloda loading, 420mg q3w) plus loading, 420mg q3w) plus • ARM B: Perjeta plus Herceptin and chemotherapy Herceptin and chemotherapy Herceptin and Xeloda • ARM B: Placebo plus • ARM B: Placebo plus Herceptin and chemotherapy Herceptin and chemotherapy

Primary • Progression-free survival • Safety, efficacy • Overall survival endpoint

Status • Recruitment completed Q3 • Recruitment completed Q4 • FPI Q2 2013 2013 2012 • PK endpoint met • Data presented at ECC 2013

63 ECC=European Cancer Congress Kadcyla (T-DM1) Evaluating new treatment options in HER2-positive breast cancer

Pretreated Previously untreated Patient Patients who have progressed on HER2 pos. metastatic breast HER2 pos. metastatic breast population HER2 targeted treatment cancer1 cancer Phase III Phase III Phase III Phase/study TH3RESA EMILIA MARIANNE # of patients N=600 N=991 N=1,092 Design • ARM A: Kadcyla 3.6mg/kg q3w • ARM A: Kadcyla 3.6mg/kg q3w • ARM A: Herceptin plus taxane • ARM B: physician’s choice • ARM B: Xeloda plus lapatinib • ARM B: Kadcyla 3.6mg/kg q3w plus Perjeta • ARM C: Kadcyla 3.6 mg/kg q3w plus placebo Primary • Progression free survival and Co-primary endpoints: • Progression-free survival assessed endpoint overall survival • Progression-free survival (PFS) by IRF • Overall survival

Status • PFS endpoint met Q2 2013 • PFS data presented at ASCO 2012 • Recruitment completed Q2 2012 • Data presented at ECC 2013 • OS data presented at ESMO 2012 • Expect data in 2014 • Submitted for FDA and EMA approval Q3 2012 • FDA approval granted Q1 2013 • Positive CHMP opinion received Q3 2013

In collaboration with ImmunoGen, Inc. 1 Patients must have received prior treatment which included both: a taxane, alone or in combination with another agent, and Herceptin in the 64 adjuvant, locally advanced, or metastatic setting. ASCO=American Society of Clinical Oncology; ESMO=European Society for Medical Oncology; ECC=European Cancer Congress Kadcyla (T-DM1) Evaluating new treatment options in HER2-positive breast and gastric cancers

Previously Treated Locally Patient HER2-positive early breast cancer Advanced Or Metastatic Her2- population high-risk patients Positive Gastric Cancer

Phase III Phase II/III Phase/study KATHERINE GATSBY

# of patients N=1,484 N=412

Design • ARM A: Kadcyla 3.6mg/kg q3w • ARM A: Kadcyla 3.6mg/kg q3w • ARM B: Herceptin • ARM B: Kadcyla 2.4mg/kg weekly • ARM C: Docetaxel or paclitaxel

Primary • Invasive disease-free survival (IDFS) • Phase II: Dose-finding endpoint • Phase III: Overall survival

Status • FPI Q1 2013 • FPI Q3 2012

65 In collaboration with ImmunoGen, Inc. Tarceva New approaches to treating lung cancer

Patient Adjuvant non-small population cell lung cancer

Phase III Phase/study RADIANT

N=974 # of patients (2:1 randomisation) Design • Following surgical resection ± adjuvant chemotherapy: • ARM A: Tarceva up to 2 years • ARM B: Placebo up to 2 years

Primary • Disease-free survival endpoint • EGFR IHC and/or FISH-positive Status • Enrolment completed Q3 2010 • Expect final results H2 2013

66 Tarceva is a registered trademark of OSI Pharmaceuticals, LLC, a subsidiary of Astellas US, LLC Zelboraf® A selective novel small molecule that inhibits mutant BRAF

Adjuvant therapy in patients Previously treated papillary Melanoma patients with Patient with resected cutaneous thyroid cancer brain metastases population BRAF mutation positive BRAF mutation positive BRAF mutation positive melanoma

Phase III Phase/study Phase II Phase II BRIM8

# of patients N=725 N=50 N=132

Design 52-week treatment • Single ARM: Zelboraf • Single ARM: Zelboraf • ARM A: Zelboraf 960mg bid • ARM B: Placebo

Primary • Disease-free survival • Best overall response rate • Overall response rate in the endpoint brain

Status • FPI Q3 2012 • Recruitment completed Q3 • Recruitment completed Q3 2013 2013 • Data presented at ECC 2013 • To be presented at SMR 2013

In collaboration with Plexxikon, a member of Daiichi Sankyo Group 67 ECC=European Cancer Congress; SMR=Society for Melanoma Research See also combinations with: cobimetinib (MEK inhibitor) and anti-PDL1 (RG7446) Erivedge A novel small molecule inhibitor of the hedgehog signaling pathway

Acute myelogenous leukemia and Patient Operable basal Locally advanced or metastatic relapsed refractory high-risk population cell carcinoma basal cell carcinoma myelodysplastic syndrome Phase II Phase/study Phase II Phase II STEVIE # of patients N=74 N=1,200 N=60 Design • Single ARM: 150 mg Erivedge • Single ARM: 150 mg Erivedge • ARM A: 150mg Erivedge orally orally once daily orally once daily once daily • ARM B: Cytarabine Primary • COHORT 1: Complete clearance (12 • Safety: incidence of adverse events • Overall response rate endpoint weeks Erivedge) • COHORT 2: Durable complete clearance (12 weeks Erivedge) • COHORT 3: Complete clearance (16 weeks Erivedge) Status • Recruitment completed Q3 2013 • FPI Q2 2011 • FPI Q3 2013 • Cohort 1 data presented at Society for Investigative Dermatology (May 2012)

68 In collaboration with Curis Actemra/RoActemra Interleukin 6 receptor inhibitor

Patient Early moderate-to-severe Moderate-to-severe Moderate-to-severe rheumatoid population rheumatoid arthritis rheumatoid arthritis arthritis

Phase III Pivotal Phase III Phase III Phase/study SUMMACTA BREVACTA FUNCTION Subcutaneous study Subcutaneous study

# of patients N=1,162 N=1,262 N=656

Design 104 week treatment • Add-on to DMARD therapy • Add-on to DMARD therapy • ARM A: Actemra IV 8 mg/kg q4w • Weekly dosing for 104 weeks • Dosing every two weeks for 104 plus placebo MTX • ARM A: Actemra SC 162mg weeks • ARM B: Actemra IV 8 mg/kg q4w weekly plus placebo IV q4w • ARM A: Actemra SC 162mg q2w plus MTX • ARM B: Actemra IV 8mg/kg q4w • ARM B: Placebo SC q2w • ARM C: Actemra IV 4 mg/kg q4w plus placebo SC weekly plus MTX • ARM D: MTX alone

Primary • DAS28 remission at 24 weeks, 1 • ACR 20 at week 24 • ACR 20 at week 24 endpoint year and 2 years

Status • Primary endpoint met Q3 2012 • Primary endpoint met Q2 2012 • Primary endpoint met Q3 2012 • Data presented at EULAR 2013 • Presented at ACR 2012 • Presented at ACR 2012 • Filed in EU Q3 2013 • Filed in US and EU in Q4 2012 • Filed in US and EU in Q4 2012

In collaboration with Chugai 69 MTX=methotrexate; DMARD=Disease-Modifying Anti-Rheumatic Drugs EULAR=The European League Against Rheumatism, ACR=American College of Rheumatology Actemra/RoActemra Interleukin 6 receptor inhibitor

Patient Systemic sclerosis Giant Cell Arteritis population

Phase II Phase III Phase/study faSScinate GiACTA Proof-of-concept study # of patients N=86 N=250 Design Blinded 48-week treatment with weekly dosing: Part 1: 52-week blinded period •ARM A: Actemra SC 162mg • ARM A: Actemra SC 162mg qw + 26 weeks •ARM B: Placebo SC prednisone taper • ARM B: Actemra SC 162mg q2w + 26 weeks Open-label weekly dosing at weeks 49 to 96: prednisone taper •Actemra SC 162mg • ARM C: Placebo+ 26 weeks prednisone taper • ARM D: Placebo+ 52 weeks prednisone taper

Part II: • 104-weel open label extension – patients in remission followed off of the study drug; Patients with active disease receive open label Actemra SC 162mg qw Primary • Change in modified Rodnan skin score (mRSS) at • Proportion of patients in sustained remission at week endpoint week 24 52 •Safety Status • Recruitment completed Q2 2013 • FPI Q3 2013 • Expect data H1 2014

70 In collaboration with Chugai Xolair Evaluating potential in chronic idiopathic urticaria, an IgE related disease

Patient Chronic idiopathic urticaria population Patients who remain symptomatic despite treatment*

Phase III Phase III Phase III Phase/study ASTERIA I ASTERIA II GLACIAL # of patients N=300 N=300 N=320 Design Add-on therapy to H1 anti- Add-on therapy to H1 anti- Add-on therapy to H1 anti- histamines histamines histamines, H2 blockers, and/or 24 week treatment period 12 week treatment period LTRA (q4-week) (q4-week) 24 week treatment period • ARM A: Xolair 300 mg •ARM A: Xolair 300 mg (q4-week) • ARM B: Xolair 150 mg •ARM B: Xolair 150 mg •ARM A: Xolair 300 mg • ARM C: Xolair 75 mg •ARM C: Xolair 75 mg •ARM B: Placebo • ARM D: Placebo •ARM D: Placebo Primary • Change from baseline in UAS7 • Change from baseline in UAS7 •Safety endpoint weekly itch score at Week 12 weekly itch score at Week 12

Status • Enrolment completed Q1 2012 • Enrolment completed Q4 2011 • Enrolment completed Q1 2012 • Presented at EADV 2013 • Presented at AAAAI 2013 • Data presented at EAACI-WAO 2013 • Filed in US Q3 2013

In collaboration with Novartis *Refractory to H1 anti-histamines, H2 blockers, and/or leukotriene receptor antagonists (LTRAs) at the time of randomization. AAAAI=American Academy of Allergy, Asthma and Immunology 71 EAACI-WAO=European Academy of Allergy and Clinical Immunology – World Allergy Organization EADV=European Academy of Dermatology and Venereology Roche Group development pipeline

Marketed products development programmes

Roche Pharma global development programmes

Roche Pharma research and early development

Genentech research and early development

Roche Group YTD Sept 2013 sales

Diagnostics

Foreign exchange rate information 72 Onartuzumab (MetMAb, RG3638) Anti-Met monovalent antibody that inhibits HGF- mediated activation

Patient 2nd- and 3rd-line 1st line non-squamous NSCLC 1st line squamous NSCLC population Met-positive metastatic NSCLC

Phase III Phase/study Phase II Phase II MetLung # of patients N=490 N=260 N=110 Design • ARM A: Tarceva plus onartuzumab Cohort 1 • Arm A: Onartuzumab + paclitaxel + • ARM B: Tarceva plus placebo •Arm A: Onartuzumab + Avastin + platinum-based chemo (cisplatin or paclitaxel + platinum-based chemo carboplatin) (cisplatin or carboplatin) •Arm B: Placebo + Avastin + paclitaxel + • Arm B: Placebo + paclitaxel + platinum-based chemo (cisplatin or platinum-based chemo (cisplatin or carboplatin) carboplatin) Cohort 2 •Arm A: Onartuzumab + pemetrexed + platinum-based chemo (cisplatin or carboplatin) •Arm B: Placebo + pemetrexed + platinum-based chemo (cisplatin or carboplatin) Primary • Overall survival • Progression-Free Survival in the ITT • Progression-Free Survival in the ITT endpoint population population • Progression-Free Survival in Met- • Progression-Free Survival in positive patients Met-positive patients Status • Recruitment completed Q3 2013 • FPI Q2 2012 • FPI Q3 2012 73 Onartuzumab (MetMAb, RG3638) Anti-Met monovalent antibody that inhibits HGF- mediated activation

Patient Metastatic HER2-negative Metastatic HER2-negative population gastroesophageal cancer gastroesophageal cancer

Phase III Phase/study Phase II MetGastric # of patients N=800 N=120 Design • ARM A: Onartuzumab plus • ARM A: Onartuzumab plus mFOLFOX mFOLFOX6 • ARM B: Placebo plus mFOLFOX • ARM B: Placebo plus mFOLFOX6

Primary • Overall survival in Met-positive • Progression–free survival in ITT endpoint patients • Progression-free survival in pre- specified Met-positive patients

Status • FPI Q4 2012 • FPI Q3 2012

74 mFOLFOX6=modified FOLFOX (Folinic acid, Fluorouracil, Oxaliplatin) Onartuzumab (MetMAb, RG3638) Anti-Met monovalent antibody that inhibits HGF- mediated activation

Advanced NSCLC Patient 1st-line metastatic Avastin-naïve recurrent Hepatocellular Met-positive with EGFR population colorectal cancer glioblastoma carcinoma activating mutation

Phase Phase II Phase II Phase I Phase III

# of patients N=188 N=120 N=54 N=300

Design • ARM A: FOLFOX plus • Arm A: Onartuzumab + • Single-agent • Arm A: Onartuzumab + Avastin plus Avastin onartuzumab in Tarceva onartuzumab • Arm B: Placebo + combination with • Arm B: Placebo + • ARM B: FOLFOX plus Avastin sorafenib Tarceva Avastin plus placebo • Arm C: Onartuzumab +Placebo (enrolment to arm C suspended) Primary • Progression–free survival • Progression-Free Survival • Safety • Progression-Free Survival endpoint in ITT in the ITT population • Progression-free survival • Progression-Free Survival in pre-specified Met- in Met-positive positive patients population

Status • Enrolment completed Q4 • FPI Q3 2012 • FPI Q3 2013 • Expect FPI Q4 2013 2012 • Expect data 2014

75 FOLFOX=Folinic acid, Fluorouracil, Oxaliplatin Cobimetinib (RG7421, GDC-0973) Selective small molecule inhibitor of mitogen- activated protein kinase kinase

Previously untreated Patient Metastatic melanoma metastatic melanoma Solid tumors Solid tumors population BRAF mutation positive BRAF mutation positive

Phase III Phase Ib Phase/study Phase Ib Phase Ib coBRIM BRIM7 # of patients N=500 N=~100 N=212 N=108 Design • ARM A: Zelboraf1 plus • Dose escalation study • Dose escalation study • Dose escalation study cobimetinib evaluating Zelboraf1 evaluating cobimetinib of cobimetinib in • ARM B: Zelboraf1 plus plus cobimetinib plus pictilisib (PI3 combination with placebo kinase inhibitor) ipatasertib2 (AKT inhibitor)

Primary • Progression-free •Safety/PK •Safety/PK •Safety/PK endpoint survival

Status • FPI Q1 2013 • FPI Q1 2011 • FPI Q4 2009 • FPI Q2 2012 • Expect data 2014 • Data presented at • Updated data presented ESMO 2012 at ASCO 2012 • Updated data presentation at EADO and ECC 2013

Cobimetinib in collaboration with Exelixis 76 1Zelboraf In collaboration with Plexxikon, a member of Daiichi Sankyo Group; 2ipatasertib in collaboration with Array BioPharma ESMO=European Society for Medical Oncology; ECC=European Cancer Congress; EADO=European Association of Dermato-Oncology Obinutuzumab (GA101, RG7159) Type II, glycoengineered anti-CD20 monoclonal antibody

Front-line Previously untreated or Patient Previously untreated chronic chronic lymphocytic leukaemia relapsed/refractory chronic population lymphocytic leukaemia (CLL) Patients with comorbidities lymphocytic CLL

Phase III Phase I Phase III Phase/study CLL11 GALTON GREEN

# of patients N=781 N=41 N=800

Design • ARM A: GA101 1000mg iv plus chlorambucil • Cohort A: GA101 plus bendamustine • Single-arm cohort study: GA101 alone • ARM B: MabThera/Rituxan plus chlorambucil • Cohort B: GA101 plus fludarabine or in combination with different • ARM C: Chlorambucil alone plus cyclophosphamide chemotherapy regimens (FC, Bendamustin or Clb)

Primary • Progression-free survival • Safety • Safety in combination with different endpoint chemotherapy regimens Status • Stage 1 analysis (ARM A/B vs. ARM C) • Recruitment completed • Expect FPI Q4 2013 positive • Expect data presentation late 2013 • Stage 1 analysis presented at ASCO 2013 • Breakthrough status and priority review granted by the FDA Q2 2013 • Filed globally Q2 2013 • Stage 2 analysis (ARM A vs. ARM B) positive • Updated Stage 1 and Stage 2 results to be presented at ASH

77 In collaboration with Biogen Idec ASCO=American Society of Clinical Oncology, ASH=American Society of Hematology Obinutuzumab (GA101, RG7159) Type II, glycoengineered anti-CD20 monoclonal antibody

Indolent Patient Diffuse large B-cell lymphoma Front-line indolent non-Hodgkin’s lymphoma population (DLBCL) non-Hodgkin’s lymphoma MabThera/Rituxan refractory Phase III Phase III Phase III Phase/study GADOLIN GOYA GALLIUM # of patients N=360 N=1,400 N=1,400 Design • ARM A: GA101 1000mg iv plus • ARM A: GA101 1000mg iv plus • ARM A: GA101 1000mg iv plus bendamustine CHOP chemotherapy followed by GA101 • ARM B: bendamustine • ARM B: MabThera/Rituxan plus maintenance CHOP • ARM B: MabThera/Rituxan plus chemotherpy followed by MabThera/Rituxan maintenance

Chemotherapy: • For follicular lymphoma: CHOP, CVP or bendamustine • For non-follicular lymphoma: physician’s choice Primary • Progression-free survival • Progression-free survival • Progression-free survival endpoint Status • FPI Q2 2010 • FPI Q3 2011 • FPI Q3 2011 • Expect data 2015 • Expect data 2015 • Expect data 2017

78 In collaboration with Biogen Idec CHOP=Cyclophosphamide, Doxorubicin, Vincristine and Prednisone; CVP=Cyclophosphamide, Vincristine and Prednisolone Bcl-2 inhibitor (RG7601, GDC-0199) Novel small molecule Bcl-2 selective inhibitor

Relapsed/Refractory Relapsed/Refractory Patient Relapsed/Refractory Relapsed/Refractory Relapsed CLL and SLL or previously or previously population CLL with 17p deletion CLL and NHL untreated CLL untreated CLL

Phase/study Phase II Phase Ib Phase I Phase I Phase I

# of patients N=100 N=50 N=52 N=70 N=70

Design • Single-agent RG7601 • Dose-escalation study • Dose-escalation study • RG7601 in combination • RG7601 in combination in combination with with with obinutuzumab MabThera/Rituxan MabThera/Rituxan and (GA101) bendamustine Primary • Safety/MTD • Safety/MTD • Safety/PK/Response • Safety/MTD • Safety/MTD endpoint rate

Status • FPI Q3 2013 • FPI Q3 2012 • FPI Q2 2011 • FPI Q2 2013 • FPI Q4 2012 • NHL data presented at ASH 2012 • CLL and NHL data presented at ASCO 2013

Joint project with AbbVie in collaboration with WEHI (The Walter and Eliza Hall Institute) 79 CLL=Chronic Lymphocytic Leukemia; NHL=Non-Hodgkin's Lymphoma; SLL=Small Lymphocytic Lymphoma ASH=American Society of Hematology; ASCO=American Society of Clinical Oncology Bcl-2 inhibitor (RG7601, GDC-0199) Novel small molecule Bcl-2 selective inhibitor

Patient Relapsed/Refractory multiple myeloma Relapsed/Refractory multiple myeloma population

Phase/study Phase I Phase I

# of patients N=30 N=30 Design Patients receiving Bortezomib and • Dose escalation cohort Dexamethasone as standard therapy: • Safety expansion cohort • Dose escalation cohort: RG7601+bortezomib+dexamethasone • Safety expansion cohort: RG7601+bortezomib+dexamethasone Primary • Safety/MTD • Safety/MTD endpoint Status • FPI Q4 2012 • FPI Q4 2012

80 Joint project with AbbVie in collaboration with WEHI (The Walter and Eliza Hall Institute) Anti-PDL1 (MPDL3280A, RG7446) Novel approach in cancer immunotherapy

Locally advanced or Locally advanced or Patient metastatic NSCLC metastatic NSCLC Solid tumors population PD-L1 positive (2nd/3rd line)

Phase II Phase II Phase/study Phase I FIR POPLAR # of patients N=100 N=180 N=344 Design Single arm study • ARM A: RG7446 1200mg IV • Dose escalation study • 1200mg of Anti-PDL1 q3w q3w, up to 16 cycles for maximum of 16 cycles • ARM A: Docetaxel IV q3w

Primary • Efficacy and safety • Overall survival • Safety/PK endpoint

Status • FPI Q2 2013 • FPI Q3 2013 • FPI Q2 2011 • Initial efficacy data presented at ASCO 2013 • Updated data presented at ECC 2013

81 ASCO=American Society of Clinical Oncology; ECC=European Cancer Congress Anti-PDL1 (MPDL3280A, RG7446) Novel approach in cancer immunotherapy

Previously untreated Patient Solid tumors metastatic melanoma BRAF population mutation positive

Phase/study Phase I Phase I

# of patients N=68 N=44 Design • ARM A: Anti-PDL1+Avastin • Three-arm study with different • ARM B: Anti-PDL1+Avastin+ doses of anti-PDL1-Zelboraf chemotherapy combination

Primary •Safety/PK •Safety/PK endpoint Status • FPI Q2 2012 • FPI Q3 2012

82 Alectinib (ALK inhibitor, RG7853, AF802) New potent inhibitor of anaplastic lymphoma kinase

Patient Non-small cell lung cancer population

Phase Phase I Phase II

# of patients N=90-100 N=215 Design • Dose escalation to MTD Patients with ALK mutation that failed crizotinib • Part 1: Dose escalation monotherapy • Part 2: Monotherapy, dose selected based on the results of Part 1 Primary • Safety and efficacy • Safety and efficacy endpoint Status • Study in crizotinib-naïve patients in • FPI Q2 2013 Japan completed; crizotinib-failure patients in US ongoing • Data presented at ECC 2013 • Japan study results: Lancet Oncology 2013 Jun;14(7):590-8 • Filed in Japan October 2013 • Breakthrough designation granted by the FDA in Q3 2013

83 In collaboration with Chugai ECC=European Cancer Congress Lebrikizumab (RG3637) A humanized monoclonal antibody designed to bind specifically to IL-13

Severe uncontrolled adult asthma

Patient Adult patients whose population asthma is uncontrolled with inhaled corticosteroids and a second controller medication

Phase III Phase III Phase/study LAVOLTA I LAVOLTA II

# of patients N=1050 N=1050

Design Subcutaneous lebrikizumab q4w on top of SOC for 52 Subcutaneous lebrikizumab q4w on top of SOC for 52 weeks safety follow-up weeks safety follow-up •ARM A: Lebrikizumab high dose •ARM A: Lebrikizumab high dose •ARM B: Lebrikizumab low dose •ARM B: Lebrikizumab low dose •ARM C: Placebo •ARM C: Placebo Patients will be tested for periostin level Patients will be tested for periostin level

Primary • Rate of asthma exacerbations during the 52-week • Rate of asthma exacerbations during the 52-week endpoint placebo-controlled period placebo-controlled period

Status • FPI Q3 2013 • FPI Q3 2013

84 Lebrikizumab (RG3637) A humanized monoclonal antibody designed to bind specifically to IL-13

Severe uncontrolled adult asthma

Patient Adult patients whose population asthma is uncontrolled with inhaled corticosteroids and a second controller medication

Phase IIb Phase IIb Phase/study LUTE VERSE

# of patients N=258 N=205

Design Subcutaneous lebrikizumab q4w on top of SOC for 28 to Subcutaneous lebrikizumab q4w on top of SOC for 28 to 52 weeks with a 24 week safety follow-up 52 weeks with a 24 week safety follow-up •ARM A: Lebrikizumab highest dose •ARM A: Lebrikizumab highest dose •ARM B: Lebrikizumab middle dose •ARM B: Lebrikizumab middle dose •ARM C: Lebrikizumab lowest dose •ARM C: Lebrikizumab lowest dose •ARM D: Placebo •ARM D: Placebo Patients will be tested for periostin level Patients will be tested for periostin level

Primary • Rate of asthma exacerbations during the 52-week • Rate of asthma exacerbations during the 52-week endpoint placebo-controlled period placebo-controlled period

Status • Recruitment completed Q4 2012 • Recruitment completed Q4 2012 • Data publication in 2014 • Data publication in 2014

85 Lebrikizumab (RG3637) A humanized monoclonal antibody designed to bind specifically to IL-13

Adolescent patients whose Patient asthma is uncontrolled with inhaled corticosteroids Idiopathic pulmonary fibrosis population and a second controller medication

Phase III Phase II Phase/study ACOUSTICS RIFF

# of patients N=375 N=250

Design Subcutaneous lebrikizumab q4w on top of SOC for 52 •ARM A: Lebrikizumab SC q4w weeks with 52 week double-blind active treatment •ARM B: Placebo extension ARM A: Lebrikizumab high dose, week 1-104 or week 52-104 •ARM B: Lebrikizumab low dose, week 1-104 or week 52-104 •ARM C: Placebo, week 1-52

Primary • Rate of asthma exacerbations during the 52-week • Progression-free survival endpoint placebo-controlled period

Status • FPI Q3 2013 • Expect FPI Q4 2013

86 Etrolizumab (RG7413) A humanized monoclonal antibody against beta 7 integrin

Patient Ulcerative colitis population

Phase II Phase/study EUCALYPTUS

# of N=120 patients Design ARM A: Etrolizumab (100mg) plus immunosuppressant ARM B: Etrolizumab (300mg) plus immunosuppressant •ARM C: Placebo plus immunosuppressant

Primary • Clinical Remission (Mayo Clinic Score) at Week 10 endpoint

Status • Primary endpoint met Q4 2012 • Presented at DDW 2013

87 DDW=Digestive Disease Week Bitopertin (GlyT-1, RG1678) A small molecule first-in-class glycin reuptake inhibitor (GRI)

Patient Sub-optimally controlled symptoms of schizophrenia population

Phase III Phase III Phase III Phase/study NIGHTLYTE MOONLYTE TWILYTE

# of patients N=600 N=600 N=600

Design •Add-on therapy to anti- •Add-on therapy to anti- •Add-on therapy to anti- psychotics psychotics psychotics •52-week treatment period •52-week treatment period •52-week treatment period •ARM A: bitopertin daily •ARM A: bitopertin daily •ARM A: bitopertin daily (10 mg) (10 mg) (5 mg) •ARM B: bitopertin daily •ARM B: bitopertin daily •ARM B: bitopertin daily (20 mg) (20 mg) (10 mg) •ARM C: Placebo •ARM C: Placebo •ARM C: Placebo

Primary •PANSS positive symptom •PANSS positive symptom •PANSS positive symptom endpoint factor at week 12 factor at week 12 factor at week 12

Status •FPI Q4 2010 •FPI Q4 2010 •Recruitment completed Q3 2013

88 PANSS=Positive and Negative Syndrome Scale Bitopertin (GlyT-1, RG1678) A small molecule first-in-class glycin reuptake inhibitor (GRI)

Patient Persistent, predominant Obsessive-compulsive population negative symptoms of schizophrenia disorder

Phase III Phase III Phase III Phase II Phase/study SUNLYTE DAYLYTE FLASHLYTE SKYLITE

# of patients N=630 N=630 N=630 N=99

Design •Add-on therapy to anti- •Add-on therapy to anti- •Add-on therapy to anti- •16-week treatment psychotics psychotics psychotics period •52-week treatment •52-week treatment •52-week treatment •Background therapy of period period period selective serotonin •ARM A: bitopertin (10 •ARM A: bitopertin (5 •ARM A: bitopertin (10 reuptake inhibitors mg) mg) mg) (SSRI) •ARM B: bitopertin (20 •ARM B: bitopertin (10 •ARM B: bitopertin (20 •ARM A: bitopertin mg) mg) mg) daily (30 mg) •ARM C: Placebo •ARM C: Placebo •ARM C: Placebo •ARM B: bitopertin daily (10 mg) •ARM C: Placebo Primary •PANSS negative •PANSS negative •PANSS negative •Change in total score on endpoint symptom factor at week symptom factor at week symptom factor at week Yale-Brown Obsessive 24 24 24 Compulsive Scale Status •FPI Q4 2010 •Enrolment completed Q2 •Enrolment completed Q2 •FPI Q4 2012 2013 2013

89 PANSS=Positive and Negative Syndrome Scale Ocrelizumab (RG1594) 2nd generation anti-CD20 monoclonal antibody

Patient Primary progressive Relapsing multiple sclerosis (RMS) population multiple sclerosis (PPMS)

Phase III Phase III Phase III Phase/study OPERA I OPERA II ORATORIO

# of patients N=800 N=800 N=630

Design • 96-week treatment period: • 96-week treatment period: • 120-week treatment period: • ARM A: Ocrelizumab 2x 300 • ARM A: Ocrelizumab 2x 300 • ARM A: Ocrelizumab 2x 300 mg iv followed by 600 mg iv mg iv followed by 600 mg iv mg iv every 24 weeks every 24 weeks every 24 weeks • ARM B: Placebo • ARM B: Interferon β-1a • ARM B: Interferon β-1a

Primary • Annualized relapse rate at 96 • Annualized relapse rate at 96 • Sustained disability progression endpoint weeks versus Rebif weeks versus Rebif versus placebo by Expanded Disability Status Scale (EDSS)

Status • Enrolment completed Q1 2013 • Enrolment completed Q1 2013 • Enrolment completed Q1 2013

90 Gantenerumab (RG1450) Fully human monoclonal antibody against amyloid-beta

Patient Prodromal Alzheimer’s Disease population

Phase II/III Phase/study SCarlet RoAD

# of patients N=770

Design 104-week subcutaneous treatment period •ARM A: Gantenerumab (225 mg) •ARM B: Gantenerumab (105 mg) •ARM C: Placebo

Primary • Change in CDR-SOB at 2 years endpoint • Sub-study: change in brain amyloid by PET at 2 years

Status • FPI Q4 2010 • Phase I PET data: Archives of Neurology 2012 Feb;69(2):198-207

In collaboration with Morphosys 91 CDR-SOB=Clinical Dementia Rating scale Sum of Boxes Mericitabine (RG7128) Nucleoside NS5B polymerase inhibitor added to approved protease inhibitors in prior null responders to IFN/RBV

Treatment-naive and failure Treatment-naive and failure Patient chronic hepatitis C chronic hepatitis C population Genotype 1 and 4 Genotype 1 and 4 Phase IIb Phase IIb Phase/study DYNAMO 2 DYNAMO 1* Longer duration study # of patients N=120 N= 120 Design • ARM A: Boceprevir + mericitabine (1000 mg BID) + • ARM A: Telaprevir + mericitabine (1000 mg BID) + Pegasys and Pegasys and Copegus for 24 weeks Copegus for 12 weeks, followed by + mericitabine (1000 mg • ARM B: Boceprevir + mericitabine (1000 mg BID) + BID) + Pegasys and Copegus for 12 weeks Pegasys and Copegus for 24 weeks followed by • ARM B: Telaprevir + mericitabine (1000 mg BID) + Pegasys and boceprevir+Pegasys and Copegus for 24 weeks Copegus for 12 weeks, followed by + mericitabine (1000 mg • ARM C : Boceprevir+Pegasys and Copegus BID) + Pegasys and Copegus for 12 weeks, followed by Pegasys for 48 weeks and Copegus for 24 weeks • ARM C : Telaprevir + mericitabine (1000 mg BID) + Pegasys and Copegus for 12 weeks, followed by Pegasys and Copegus for 36 weeks • ARM D: Telaprevir + Pegasys and Copegus for 12 weeks, followed by Pegasys and Copegus for 36 weeks Primary • Sustained virological response (SVR) • Sustained virological response (SVR) endpoint Status • Recruitment completed Q3 2012 • Recruitment completed Q3 2012 • Data submitted to AASLD 2013 • Data submitted to AASLD 2013

92 Mericitabine (RG7128) licensed from Pharmasset, now part of Gilead * In collaboration with Merck Mericitabine, danoprevir, setrobuvir IFN-free combination of different direct-acting antivirals in treatment naïve patients

Hepatitis C patients Patient population Treatment-naïve or null-responders to interferon-based treatment

Phase II Phase/study ANNAPURNA

# of patients N=110

Design • ARM A: GT1a including setrobuvir, danoprevir, ritonavir, ribavirin and mericitabine • ARM B: GT1a including setrobuvir, danoprevir, ritonavir, ribavirin and mericitabine • ARM C: GT1a including setrobuvir, danoprevir, ritonavir and ribavirin • ARM D: GT1b including setrobuvir, danoprevir, ritonavir, ribavirin and mericitabine • ARM E: GT1b including setrobuvir, danoprevir, ritonavir and ribavirin

Primary endpoint • Sustained virological response at week 12 after the end of the study treatment

Status • FPI Q2 2012 • Recruitment Part 1 completed in Q4 2012 • Interim data submitted to AASLD 2013

93 Mericitabine (RG7128) licensed from Pharmasset, now part of Gilead; Danoprevir=RG7227; Setrobuvir=RG7790 AASLD=American Association for the Study of Liver Diseases Danoprevir, mericitabine Comparing IFN-free, IFN-based triple and IFN-based quad regimens in patients who failed IFN/RBV

Patient Treatment-experienced population chronic hepatitis C patients* Phase IIb Phase Matterhorn Boosted Danoprevir in Triple, Quad and Interferon-free combinations # of patients N=381

Design Danoprevir boosted by low dose ritonavir in IFN-free, triple and QUAD Cohort A: partial responders: •ARM A1: Danoprevir 100 mg bid+ Ritonavir 100mg bid+ mericitabine 1000 mg bid + Copegus for 24 weeks •ARM A2: Danoprevir 100 mg bid + Ritonavir 100mg bid+ Pegasys + Copegus for 24 weeks •ARM A3: Danoprevir 100 mg bid + Ritonavir 100mg bid + mericitabine 1000 mg bid + Pegasys + Copegus for 24 weeks Cohort B: null responders: •ARM B1: Danoprevir 100 mg bid + Ritonavir 100mg bid + mericitabine 1000 mg bid + Copegus for 24 weeks •ARM B2: Danoprevir 100 mg bid + Ritonavir 100mg bid+ mericitabine 1000 mg bid + Pegasys + Copegus for 24 weeks •ARM B3: Danoprevir 100 mg bid+ Ritonavir 100mg bid + mericitabine 1000 mg bid + Pegasys + Copegus for 24 weeks, followed by 24 weeks Pegasys + Copegus

Primary • Sustained virological response 24 weeks after the end of study treatment endpoint Status • Recruitment completed Q3 2011 • Preliminary data presented at AASLD 2012 • Manuscript submission late 2013

94 Mericitabine (RG7128) licensed from Pharmasset, now part of Gilead; Danoprevir=RG7227 AASLD=American Association for the Study of Liver Diseases Roche Group development pipeline

Marketed products development programmes

Roche Pharma global development programmes

Roche Pharma research and early development

Genentech research and early development

Roche Group YTD Sept 2013 sales

Diagnostics

Foreign exchange rate information 95 Oncology development programmes Small molecules

MDM2 (4) antagonist MEK inhibitor Raf/MEK inhibitor Molecule (RG7388) (CIF, RG7167) (CKI27, RG7304) Patient Solid tumors Acute myeloid leukemia Solid tumors Solid tumors population Phase Phase I Phase I Phase I Phase I # of patients N=100 N=100 N=144 N=52 Design • Multiple ascending • Multiple ascending • Dose-escalation, • Dose-escalation to MTD dose-escalation study dose-escalation study followed by expansion into 4 cohorts in specific indications

Primary • MTD • MTD • MTD and tumor • MTD and tumor endpoint assessment assessment Status • Completed Q2 2013 • FPI Q1 2013 • Recruitment into • Initiated Q4 2008 expansion cohorts • Enrolment stopped in Q4 completed Q4 2011 2010 • Data presented at EORTC-NCI-AACR 2012

Collaborator Chugai

96 Oncology development programmes Monoclonal antibodies

Anti-glypican-3 MAb Anti-CD44 MAb Molecule (GC33, RG7686) (RG7356)

Patient Metastatic liver cancer 2L metastatic liver cancer Acute myelogenous Solid tumors population (hepatocellular carcinoma) (hepatocellular carcinoma) leukemia

Phase Phase Ib Phase II Phase I Phase I

# of patients N= 40-50 N=171 N=50-70 N=86

Design • Study US monotherapy Adaptive design study • Multiple ascending dose • Multiple ascending dose • Study Japan monotherapy Double blind randomized 2:1 study with extension and study +/- cytarabine • Dose escalation study in RG7686 : placebo imaging arm combo with SoC Patients are stratified according to the level of GPC- 3 expression in tumor Primary • Safety and tolerability • Progression-free survival • Safety (MTD), PK, PD, • Safety (MTD), PK, PD, endpoint preliminary clinical activity preliminary clinical activity

Status • FPI Q4 2008 • Recruitment completed Q1 • FPI Q2 2011 • FPI Q3 2012 • Dose escalation completed 2013 for US and Japan • Final results expected H2 monotherapy studies 2013 • Dose escalation ongoing for Ph1b combo with SoC

Collaborator Chugai

97 SoC=standard of care Oncology development programmes Monoclonal antibodies (continued)

Anti-TWEAK MAb GE-huMAb HER3 Molecule (RG7212) (RG7116)

HER2-low and HER3- Patient Solid tumors Solid tumors positive metastatic breast population cancer

Phase Phase I Phase I Phase I

# of patients N=50 N=105 N=40

Design • Multiple ascending dose • Multiple ascending dose • Multiple ascending dose of study study with extension RG7116 in combination cohorts and imaging sub- with Perjeta and paclitaxel study • Combination arms with HER1-targeted therapies (erlotinib, cetuximab)

Primary • Safety, PK, PD • Safety, PK • Safety, PK endpoint

Status • FPI Q3 2011 • FPI Q4 2011 • FPI Q3 2013

98 Oncology development programmes Monoclonal antibodies (continued)

CSF-1R huMAb Ang2-VEGF MAb Molecule (RG7155) (RG7221)

Patient Solid tumors Solid tumors population Phase Phase I Phase I

# of patients N≈95 N≈80 Design • Multiple ascending dose • Multiple ascending dose study +/- paclitaxel with study with extension cohort to extension cohorts assess the PD effects

Primary • Safety, PK, PD & preliminary •Safety endpoint clinical activity

Status • FPI Q4 2011 • FPI Q4 2012 • Biomarker data presented at AACR 2013

99 AACR=American Association for Cancer Research Metabolic development programmes

Inclacumab Molecule (P-selectin huMAb, RG1512)

Prevention of saphenous vein graft disease Acute Coronary Syndrome (ACS) Patient Patients undergoing coronary artery bypass graft Patients undergoing Percutaneous Coronary population (CABG) surgery Intervention (PCI)

Phase II Phase II Phase/study SELECT-CABG SELECT-ACS

# of patients N=384 N=516

Design 32-week treatment period Single infusion •ARM A: Inclacumab (20 mg/kg) •ARM A: Inclacumab (5 mg/kg) •ARM B: Placebo •ARM B: Inclacumab (20 mg/kg) •ARM C: Placebo Primary •Sapheneous vein graft re-occlusion •Procedural damage (troponin) Endpoint

Status • Recruitment completed Q2 2012 • Recruitment completed • Data in-house Q3 2013 • Data presented at ACC 2013

• Candidate for partnering-out

Collaborator Genmab

100 ACC=American College of Cardiology Metabolic development programmes

GLP-1/GIP dual agonist NME Molecule (MAR709, RG7697) (RG7410)

Patient Type 2 diabetes Metabolic diseases population

Phase/study Phase I Phase I

# of patients N=60 N=24

Design • ARM A: RG7697 SC • RG7410 single dose • AMR B: placebo •Placebo

Primary •Safety, PK •Safety Endpoint

Status • MAD study ongoing • FSI Q3 2013

Collaborator Marcadia Biotech, Inc. acquisition

101 FSI=First Subject In Neuroscience development programmes

Metabotropic glutamate receptor pathway

mGlu2 Negative Allosteric mGlu5 Negative Allosteric Modulator (NAM) Molecule Modulator (NAM) (RG7090) (RG1578) Adjunctive Treatment of Adjunctive Treatment of Patient Major Depressive Major Depressive Fragile X Syndrome population Disorder Disorder Phase II Phase II Phase II Phase II Phase/study ArtDeCo Marigold Fragxis FoXtail N=480 N=45 # of patients N=300 N=180 Pediatric patients Design • ARM A: RG1578 5 mg . ARM A: RG7090 0.5 mg . ARM A: RG7090 0.5 mg . ARM A: RG7090 Dose A • ARM B: RG1578 15 mg . ARM B: RG7090 1.5 mg . ARM B: RG7090 1.5 mg . ARM B: RG7090 Dose B • ARM C: RG1578 30 mg . ARM C: Matching . ARM C : Matching . ARM C : Matching • ARM D: Matching Placebo Placebo Placebo Placebo

Primary • Efficacy - Montgomery • Efficacy - Montgomery • Efficacy, safety and •Safety endpoint Asberg Depression Rating Asberg Depression Rating tolerability • Exploratory efficacy and Scale Scale tolerability

Status • Recruitment ongoing • Recruitment completed • Recruitment ongoing • Recruitment initiated • Expect data H1 2014 • Expect data H2 2013 • Expect data H1 2014 • Expect data H1 2014

102 Neuroscience development programmes

Monoamine oxidase type B V1 receptor antagonist PDE10A inhibitor Molecule (MAO-B) inhibitor (RG7314) (RG7203) (RG1577, EVT-302)

Patient Alzheimer’s Disease Autism Schizophrenia population

Phase IIb Phase Phase II Phase I MAyflOwer RoAD

# of patients N=495 N=150 N=53

Design • 52-week oral treatment • Multi-center, randomized, double- • Double-blind, multiple-ascending • ARM A: RG1577 (dose 1) blind, placebo-controlled proof-of- dose, placebo controlled study in • ARM B: RG1577 (dose 2) concept study in individuals with healthy volunteers • ARM C: placebo Autism Spectrum Disorder (ASD) • Open-label single-dose PET study in HV

Primary • Changes in ADAS-Cog at 52 weeks • Safety and efficacy • Safety, PK endpoint • Target engagement

Status • FPI Q4 2012 • FPI Q3 2013 • SAD completed • MAD FPI Q2 2013 • SD PET FPI Q3 2013

Collaborator Evotec

103 HV=Healthy Volunteers Neuroscience development programmes

GABRA5 negative allosteric modulator (NAM) Molecule (RG1662)

Patient Down Syndrome population

Phase Phase I Phase Ib

# of patients N=17 N=33

Design • Molecular and functional • Multi-center, randomized, imaging study in individuals double-blind, placebo- with DS and HV controlled, multiple dose study in individuals with Down Syndrome

Primary • GABAA alpha5 receptor • Safety, tolerability endpoint expression, occupancy and functional connectivity

Status • FPI Q3 2012 • Recruitment completed Q3 2013

104 DS=Down Syndrome; HV=Healthy Volunteers Infectious diseases programmes

TLR7 agonist Molecule (RG7863)

Patient Chronic hepatitis B population

Phase Phase I

# of patients N=60

Design • Healthy volunteer study • ARM A: Single ascending dose of RG7863 • ARM B: Placebo

Primary •Safety endpoint

Status • FPI Q3 2013

105 Roche Group development pipeline

Marketed products development programmes

Roche Pharma global development programmes

Roche Pharma research and early development

Genentech research and early development

Roche Group YTD Sept 2013 sales

Diagnostics

Foreign exchange rate information 106 Oncology development programmes Monoclonal antibodies

Angiogenic signaling

Parsatuzumab Molecule (Anti-EGFL7 MAb, RG7414)

Patient First-line metastatic First-line metastatic population non-small cell lung cancer colorectal cancer

Phase II Phase II Phase/study NILE CONGO

# of N=104 N=128 patients Design • Parsatuzumab plus Avastin plus • ARM A: Parsatuzumab plus carbo/tax vs Avastin plus carbo/tax Avastin plus FOLFOX • ARM B: Avastin plus FOLFOX

Primary • PFS • PFS endpoint

Status • Enrolment completed Q3 2012 • Enrolment completed Q3 2012 • Primary endpoint not met Q3 2013 • Interim analysis suggests primary endpoint unlikely to be met

*SCCHN=Squamous Cell Carcinoma of the Head and Neck; AACR=American Association for Cancer Research 107 FOLFOX=Folinic acid, Fluorouracil, Oxaliplatin; FOLFIRI=Folinic acid, Fluorouracil, Irinotecan Oncology development programmes Monoclonal antibodies

Growth factor signaling

Anti-HER3 EGFR DAF MAb Molecule (RG7597)

1L recurrent/metastatic Patient Metastatic/recurrent KRAS wild-type metastatic squamous cell carcinoma population SCCHN* colorectal cancer of head and neck

Phase II Phase II Phase/study Phase Ib MEHGAN DARECK

# of patients N=110 N=120 N=120

Design • ARM A: RG7597 • ARM A: RG7597+FOLFIRI Evaluating safety/tolerability • ARM B: Cetuximab • ARM B: with two chemo backbones Cetuximab+FOLFIRI • Arm A: Cisplatin/5-FU • Arm B: Carboplatin/Paclitaxel

Primary • Progression-free survival • Progression-free survival • Safety, DLT, PK endpoint

Status • Recruitment completed Q2 • FPI Q4 2012 • FPI Q3 2013 2013

108 *SCCHN=Squamous Cell Carcinoma of the Head and Neck; AACR=American Association for Cancer Research FOLFOX=Folinic acid, Fluorouracil, Oxaliplatin; FOLFIRI=Folinic acid, Fluorouracil, Irinotecan Oncology development programmes Antibody drug conjugates

Antibody drug conjugates (ADCs)

Anti-STEAP1 ADC Anti-MUC16 ADC NME ADC Molecule (RG7450) (RG7458) (RG7598)

Patient Prostate cancer Ovarian cancer Multiple myeloma population

Phase Phase I Phase I Phase I

# of patients N=49 N=57 N=30-45

Design • Dose escalation study • Dose escalation study • Dose escalation study

Primary • Safety • Safety/PK • Safety endpoint Status • FPI Q1 2011 • FPI Q2 2011 • FPI Q3 2011 • Data presented at ASCO 2013 • Safety and PK data presented at AACR 2013 Collaborator Seattle Genetics Seattle Genetics and Agensys

109 AACR=American Association for Cancer Research, ASCO=American Society of Clinical Oncology Oncology development programmes Antibody drug conjugates (continued)

Antibody drug conjugates (ADCs)

Anti-NaPi ADC ADC NME ADC Anti-ETBR ADC Molecule (RG7599) (RG7600) (RG7636)

Patient Metastatic or unresectable NSCLC and ovarian cancer Pancreatic and ovarian cancer population melanoma

Phase Phase I Phase I Phase I

# of patients N=70 N=66-96 N=44-64

Design • Dose escalation study • Dose escalation study • Dose escalation study

Primary •Safety •Safety •Safety endpoint Status • FPI Q2 2011 • FPI Q4 2011 • FPI Q1 2012 • Safety and efficacy data presented at ASCO 2013 Collaborator Seattle Genetics

110 ASCO=American Society of Clinical Oncology Oncology development programmes ADC’s for hematological cancers

Antibody drug conjugates (ADCs)

Pinatuzumab vedotin (RG7593) Pinatuzumab vedotin Polatuzumab vedotin Molecule vs. polatuzumab vedotin (Anti-CD22, RG7593) (Anti-CD79b, RG7596) (RG7596)

Patient Hematologic Non-Hodgkin's Lymphoma Hematologic malignancies population malignancies Phase Phase I Phase II Phase I

# of patients N=76 N=120 N=99

Design • Dose escalation study • RG7593 plus Rituxan • Dose escalation study • RG7596 plus Rituxan

Primary • Safety • Safety and anti-tumor activity • Safety endpoint Status • Recruitment completed Q4 2012 • FPI Q3 2012 • Recruitment completed Q4 2012 • Dose escalation data presented at • Dose escalation data presented at ASH 2012 ASH 2012 • Efficacy data presented at ICML • Efficacy data presented at ICML 2013 2013 Collaborator Seattle Genetics

111 ASH=American Society of Hematology; ICML=International Conference on Malignant Lymphoma Oncology development programmes Small molecules

PI3K signaling

Pictilisib Molecule (PI3 Kinase inhibitor, GDC-0941, RG7321)

Locally recurrent or metastatic Patient Previously untreated advanced or 2L ER+ metastatic breast cancer HER2-negative HR-positive population recurrent NSCLC breast cancer Phase II Phase II Phase II Phase FERGI FIGARO PEGGY

# of patients N=340 N=302 N=180

Design • ARM A: pictilisib plus hormonal • ARM A: Pictilisib + carboplatin + • ARM A: Pictilisib+ paclitaxel therapy paclitaxel • ARM B: Placebo + paclitaxel • ARM B: apitolisib plus hormonal • ARM B: Placebo + carboplatin + therapy (ARM B discontinued) paclitaxel • ARM C: Hormonal therapy + • ARM C: Pictilisib+ carboplatin + placebo paclitaxel + bevacizumab • ARM D: Pictilisib+ carboplatin + paclitaxel + bevacizumab Primary • Progression-free survival • Progression-free survival • Progression-free survival endpoint Status • FPI Q3 2011 • FPI Q1 2012 • FPI Q1 2013

112 Oncology development programmes Small molecules (continued)

PI3K signaling

PI3 Kinase inhibitor PI3 Kinase inhibitor Molecule (GDC-0032, RG7604) (GDC-0084, RG7666)

Patient Solid tumors and HER2-negative HER2-negative locally recurrent Progressive or recurrent high- population HR-positive breast cancer or metastatic breast cancer grade glioma

Phase Phase I/II Phase I Phase I

# of patients N=260 N=65 N=68

Design Phase I • RG7604 plus docetaxel • Dose escalation study • RG7604 • RG7604 plus paclitaxel • RG7604 plus letrozole or fulvestrant

Phase II • RG7604 plus fulvestrant Primary • Safety/PK/efficacy • Safety • Safety/PK endpoint

Status • FPI Q1 2011 • FPI Q2 2013 • FPI Q2 2012 • Pre-clinical and clinical data presented at AACR 2013

113 AACR=American Association for Cancer Research Oncology development programmes Small molecules (continued)

PI3K signaling

Apitolisib Molecule (PI3 Kinase/mTOR dual inhibitor, GDC-0980, RG7422)

Patient Persistent or recurrent 2L Castration-resistant Renal cell carcinoma population endometrial carcinoma prostate cancer

Phase II Phase II Phase Phase Ib/II ROVER MAGGIE

# of patients N=80 N=50 N=262

Design • ARM A: apitolisib • Single-arm apitolisib • ARM A: RG7440 + • ARM B: Everolimus abiraterone • ARM B: apitolisib + abiraterone • ARM C: Placebo + abiraterone

Primary •PFS •PFS •Safety (PhIb) endpoint • PFS (Ph II)

Status • Enrolment completed Q3 • Enrolment completed Q3 • FPI Q1 2012 2012 2012

114 Oncology development programmes Small molecules (continued)

Ipatasertib Molecule (AKT inhibitor, GDC-0068, RG7440)

1L metastatic gastric or Patient 2L Castration-resistant Solid tumors Solid tumors gastroesophageal junction population prostate cancer adenocarcinoma Phase Ib/II Phase II Phase Phase Ib Phase Ib A.MARTIN JAGUAR # of patients N=90 N=262 N=62 N=120 Design Dose escalation with: • ARM A: ipatasertib + • Dose escalations study of • ARM A: ipatasertib + •ARM A: docetaxel abiraterone cobimetinib (MEK mFOLFOX6 or • ARM B: apitolisib + inhibitor)* in combination • ARM B: Placebo + •ARM B: fluoropyrimidine abiraterone with ipatasertib mFOLFOX6 plus oxaliplatin • ARM C: Placebo + or abiraterone •ARM C: paclitaxel Primary •Safety •Safety (PhIB) •Safety/PK endpoint • PFS (Ph II) Status • FPI Q3 2011 • Ph II FPI Q3 2013 • FPI Q2 2012 • FPI Q3 2013 • Data presented at ASCO and ESMO 2012

Collaborator Array BioPharma

*Cobimetinib in collaboration with Exelixis 115 ASCO=American Society of Clinical Oncology; ESMO=European Society for Medical Oncology mFOLFOX6=modified FOLFOX (Folinic acid, Fluorouracil, Oxaliplatin) Oncology development programmes Small molecules (continued)

ChK1 inhibitor ChK1 inhibitor NME Molecule (GDC-0425, RG7602) (GDC-0575, RG7741) (GDC-0094, RG7842)

Patient Solid tumors or lymphoma Solid tumors or lymphoma Solid tumors population

Phase I Phase I Phase I Phase I

# of patients N=75 N=45 N=78

Design • Dose escalation study • Dose escalation study • Stage 1: dose escalation • Stage 2: cohort expansion

Primary •Safety/PK •Safety/PK •Safety, MTD, PK endpoint

Status • FPI Q3 2011 • FPI Q2 2012 • FPI Q2 2013

Collaborator Array BioPharma

116 Immunology and ophthalmology development programmes

Quilizumab Lampalizumab Molecule (Anti-M1 prime, RG7449) (Anti-Factor D, RG7417) Patient Geographic atrophy (GA) secondary to age- Allergic asthma - inadequately controlled population related macular degeneration Phase IIb Phase Ib/II Phase/study COSTA MAHALO # of patients N=560 N=143 Design SC administration on top of SoC • Part 1: Open-label •ARM A: RG7449 300mg • Multiple dosing •ARM B: RG7449 150mg • Part 2: Randomized •ARM C: RG7449 450mg • ARM A: Lampalizumab injection •ARM D: Placebo • ARM B: Sham injection

Primary • Rate of protocol-defined exacerbations from • Part 1: Safety endpoint baseline to week 36 • Part 2: Growth rate of GA lesions at month 18

Status • Recruitment completed Q3 2013 • Primary endpoint met Q3 2013, higher efficacy in a subset of patients defined by exploratory biomarkers was also described • Data presented at ASRS and EURETINA 2013 • Additional data to be presented at AAO 2013

SoC=Standard of Care 117 ASRS=American Society of Retina Specialists; EURETINA=European Society of Retina Specialists; AAO=American Academy of Ophthalmology Immunology and ophthalmology development programmes

Rontalizumab anti-IL17 Molecule (Anti-INFalpha, RG7415) (RG7624) Patient Systemic lupus erythematosus Autoimmune diseases population Phase II Phase/study Phase Ib ROSE # of patients N=238 N=21 Design • ARM A: Placebo • Randomized, double-blind, placebo- • Part 1 – iv controlled, multiple ascending dose • Part 2 - sc escalation study • ARM B: Rontalizumab • Part 1 – iv • Part 2 – sc

Primary • Proportion of responders at Week 24 • Safety and tolerability endpoint

Status • Enrolment completed Q3 2010 • Enrolment completed Q2 2012 • Data presented at ACR 2012 • Candidate for partnering-out

Collaborator NovImmune

118 ACR=American College of Rheumatology Neuroscience development programmes

Crenezumab Molecule (Anti-Αβ, RG7412)

Patient Alzheimer’s Disease population

Phase II Phase II Phase/study ABBY BLAZE Cognition study Biomarker study

# of patients N=360 N=72

Design • ARM A: Crenezumab sc • ARM A: Crenezumab sc • ARM B: Crenezumab iv • ARM B: Crenezumab iv • ARM C: Placebo • ARM C: Placebo

Primary • Change in cognition (ADAS-cog) and • Change in brain amyloid load from endpoint Clinical Dementia Rating, Sum of baseline to week 69 Boxes (CDR-SOB) score from baseline to week 73 Status • Enrolment completed Q3 2012 • Enrolment completed Q3 2012

Collaborator AC Immune

119 Metabolism and infectious diseases development programmes

Anti-PCSK9 NME targeting CMV NME Molecule (RG7652) (RG7667) (RG7745)

Prevention of Patient cytomegalovirus disease in Metabolic diseases Infectious diseases population kidney transplant recipients

Phase II Phase/study Phase II Phase I EQUATOR

# of patients N=224 N=110 N=21 Design SC dosing every 4 weeks • ARM A: RG7667 • Single ascending dose of • Experimental: five different • ARM B: Placebo RG7745 doses of RG7652 •Placebo •Placebo

Primary • Absolute change from baseline • Safety, clinical activity • Safety, PK endpoint in LDL-c concentration

Status • Phase I data presented at ESC • FPI Q4 2012 • Recruitment completed Q3 2013 2013 • Phase II data readout in 2013 • Candidate for partnering-out

120 Roche Group development pipeline

Marketed products development programmes

Roche Pharma global development programmes

Roche Pharma research and early development

Genentech research and early development

Roche Group YTD Sept 2013 sales

Diagnostics

Foreign exchange rate information 121 Geographical sales split by divisions and Group*

CHFm YTD Sep 2012 YTD Sep 2013 % change CER Pharmaceuticals Division 26,198 27,190 +7 United States 10,270 11,429 +12 Europe 6,715 6,952 +2 Japan 2,966 2,492 +3 International 6,247 6,317 +5 Diagnostics Division 7,496 7,677 +4 United States 1,713 1,706 0 Europe 2,919 3,004 +1 Japan 434 358 +1 International 2,430 2,609 +10 Group 33,694 34,867 +6 United States 11,983 13,135 +10 Europe 9,634 9,956 +2 Japan 3,400 2,850 +3 International 8,677 8,926 +7 122 * Geographical sales split shown here does not represent operational organization; CER=Constant Exchange Rates Pharma Division sales YTD Sep 2013 (vs. 2012) Top 20 products

Global US Europe Japan International CHFm % CER CHFm % CER CHFm % CER CHFm % CER CHFm % CER MabThera/Rituxan 5,206 6 2,574 10 1,446 3 180 5 1,006 -1 Avastin 4,710 13 1,984 6 1,436 16 519 17 771 24 Herceptin 4,594 6 1,375 11 1,654 -1 212 7 1,353 8 Lucentis 1,251 13 1,251 13 ------Xeloda 1,164 3 480 2 243 -2 80 5 361 8 Pegasys 1,027 -19 263 -40 276 -11 40 -19 448 -5 Tarceva 1,018 5 473 12 259 -6 70 4 216 3 Actemra/RoActemra 763 33 233 37 265 29 140 19 125 56 CellCept 681 1 158 27 179 -14 50 11 294 -1 Xolair 590 12 590 12 ------Activase/TNKase 514 18 477 19 - - - - 37 5 Valcyte/Cymevene 499 5 261 10 122 -10 - - 116 13 Tamiflu 414 81 239 159 9 -1 87 9 79 94 Pulmozyme 412 5 264 10 93 2 - 151 55 -11 NeoRec./Epogin 400 -19 - - 168 -28 76 -30 156 0 Mircera 307 25 - - 76 24 152 29 79 19 Zelboraf 260 65 95 15 142 94 - - 23 * Madopar 235 2 - - 84 -1 14 5 137 4 Nutropin 213-7208-7-- -- 5-17 Rocephin 201 5 0 -53 31 -7 32 -1 138 10

123 CER=Constant Exchange Rates * over +500% Pharma Division CER sales growth1 in % Top 20 products by region US Europe Japan International Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 MabThera/Rituxan712-1208236 5068 4-2-33 Avastin 1 3 3 10 13 15 17 17 20 18 18 15 3 26 29 19 Herceptin 11 17 1 14 4 1 -2 -1 12 6 7 7 10 19 -1 8 Lucentis -911821------Xeloda 6 0 -3 8 -1 -4 -2 1 12 8 5 3 4 3 13 10 Pegasys -17 -30 -40 -51 -2 -10 -8 -14 -6 -16 -18 -22 2 -4 -21 18 Tarceva 5 14 18 5 -11 -12 -4 0 6 8 -2 8 -11 -12 12 13 Actemra/RoActemra 58 45 33 33 35 29 31 26 -7 8 23 26 63 53 57 59 CellCept 0 60 17 13 -13 -13 -18 -11 14 8 13 13 10 -4 6 -5 Xolair 10 12 10 14 ------Activase/TNKase 17 36 3 19 ------20 27 -5 -1 Valcyte/Cymevene 18 4 14 10 -8 -1 -5 -22 - - - - 13 27 9 3 Tamiflu - 171 -41 * - 54 -58 -76 57 6 121 -73 164 132 161 -17 Pulmozyme 8 17 8 6 6 -3 4 6 - - 308 29 -5 -6 5 -25 NeoRec./Epogin - - - - -23 -25 -31 -26 -46 -37 -29 -22 0 -3 2 3 Mircera - - - - -57 -32 142 74 83 46 21 26 6 28 19 11 Zelboraf 44191512* *5136- - - - - * *489 Madopar - - - - -5 -3 -2 2 11 8 3 5 13 17 -6 3 Nutropin -5 -6 -8 -7 ------17 -13 -12 -25 Rocephin -15 -62 -65 13 -13 -14 5 -9 -11 -8 2 2 -1 -3 29 7 124 1 Q4 2012 vs. 2011, Q1 2013 – Q3 2013 vs. 2012 CER=Constant Exchange Rates * over +500% Pharma Division sales YTD Sep 2013 (vs. 2012) Recently launched products

Global US Europe Japan International CHFm % CER CHFm % CER CHFm % CER CHFm % CER CHFm % CER Perjeta 186 * 136 431 37 * 5 - 8 - Kadcyla 156 - 152 - 3 - - - 1 - Erivedge 48 164 46 152 2 - - - - -

125 CER=Constant Exchange Rates * over +500% Pharma Division CER sales growth1 in % Global top 20 products

Q3/12 Q4/12 Q1/13 Q2/13 Q3/13 MabThera/Rituxan 11 7 6 0 12 Avastin 11 8 11 13 14 Herceptin 14 8 11 0 7 Lucentis -12 -9 1 18 21 Xeloda 4 5 1 3 6 Pegasys -4 -5 -15 -24 -16 Tarceva -5 -3 0 9 5 Actemra/RoActemra 27 30 32 33 33 CellCept -11 1 4 1 -2 Xolair 9 10 12 10 14 Activase/TNKase 30 17 35 3 18 Valcyte/Cymevene 9 9 8 8 0 Tamiflu -64 449 84 44 115 Pulmozyme 11 4 9 7 0 NeoRec./Epogin -20 -25 -22 -20 -16 Mircera -12 2 12 35 29 Zelboraf 498 271 154 46 38 Madopar 2 5 9 -4 3 Nutropin -10 -5 -6 -8 -8 Rocephin -8 -5 -6 19 4 126 1 Q3-Q4/12 vs. Q3-Q4/11, Q1-Q3/13 vs. Q1-Q3/12 CER=Constant Exchange Rates CER sales growth (%) Quarterly development

2012 vs. 2011 2013 vs. 2012 Q1 Q2 Q3 Q4 Q1 Q2 Q3

Pharmaceuticals Division 2 6 4 7 7 4 9

United States 6 6 5 13 13 7 16 Europe -3 -1 -2 0 1 2 3 Japan 1 0 1 5 2 2 4 International 3 16 12 6 8 2 5 Diagnostics Division 4 6 1 4 1 4 7 Roche Group 2 6 4 6 6 4 8

127 CER=Constant Exchange Rates CER sales growth (%) Impact of 340B sales reserves release

2012 vs. 2011 2013 vs. 2012 excl. 340B Q1 Q2 Q3 Q4 Q1 Q2 Q3 YTD Q3 YTD Sep Sep Pharmaceuticals Division 2 6 4 7 7 4 9 7 66 MabThera/Rituxan 7 11 11 7 6 0 12 6 64 Avastin 1 5 11 8 11 13 14 13 12 12 Herceptin 7 14 14 8 11 0 7 6 45

United States 6 6 5 13 13 7 16 12 10 10 MabThera/Rituxan 8 9 9 7 12 -1 20 10 76 Avastin 0 -5 4 1 3 3 10 6 54 Herceptin 11 9 12 11 17 1 14 11 47

Roche Group 2 6 4 6 6 4 8 6 65

128 CER=Constant Exchange Rates YTD Sept 2013: Oncology franchise

Oncology sales +9%1 18 US +9% • Sales growth driven by Rituxan, Kadcyla, 15 +8% Herceptin and Perjeta, partially due to 340B reserves release 12 Europe 9 +6% • Major drivers Avastin and Zelboraf

CHFbn 6 International • Strong growth for Avastin and Herceptin 3 +12% Japan 0 • Growth driven largely by Avastin YTD 9 11 YTD 9 12 YTD 9 13

Japan International Europe US

129 1 CER=Constant Exchange Rates; Oncology sales CHF 16.9bn MabThera/Rituxan

Global sales CER growth Regional sales CER growth CHFbn +6% US +10% 6.0

5.0 Europe +3% 4.0

3.0 Japan +5%

2.0 International -1% 1.0

0.0 YTD 9 YTD 9 YTD 9 YTD 9 YTD 9 09 10 11 12 13 YTD Sept 2013 sales of CHF 5.206bn • US/Europe: Growth driven primarily by population growth • Developing market growth due largely to increased share and duration of treatment in DLBCL

130 CER=Constant Exchange Rates Avastin

Global sales CER growth Regional sales CER growth CHFbn +13% US +6% 6.0

5.0 Europe +16% 4.0

3.0 Japan +17% 2.0 International +24% 1.0

0.0 YTD 9 YTD 9 YTD 9 YTD 9 YTD 9 09 10 11 12 13 YTD Sept 2013 sales of CHF 4.710bn • Europe: strong growth driven by further uptake in ovarian and colorectal cancer (Treatment through multiple lines) • US: increase in mCRC use associated with TML awareness • Japan: steady growth in CRC, BC, NSCLC 131 CER=Constant Exchange Rates Herceptin

Global sales CER growth Regional sales CER growth CHFbn +6% 5.0 US +11%

4.0 Europe -1% 3.0

2.0 Japan +7% International +8% 1.0

0.0 YTD 9 YTD 9 YTD 9 YTD 9 YTD 9 09 10 11 12 13 YTD Sept 2013 sales of CHF 4.594bn • Volume growth driven by International region • Emerging markets: driven by access in public markets in key countries, patient access program in China and longer duration of use in early breast cancer

132 CER=Constant Exchange Rates Xeloda

Global sales CER growth Regional sales CER growth CHFbn +3% US +2% 1.2

1.0 Europe -2%

0.8 Japan +5% 0.6

0.4 International +8% 0.2

0.0 YTD 9 YTD 9 YTD 9 YTD 9 YTD 9 09 10 11 12 13 YTD Sept 2013 sales of CHF 1.164bn • US: supply of IV 5FU normalised. Brand approaching end of lifecycle • Sales growth in the International region driven by China

133 CER=Constant Exchange Rates Tarceva

Global sales CER growth Regional sales CER growth CHFbn +5% US +12% 1.2

1.0 Europe -6% 0.8 Japan +4% 0.6

0.4 International +3% 0.2

0.0 YTD 9 YTD 9 YTD 9 YTD 9 YTD 9 09 10 11 12 13 YTD Sept 2013 sales of CHF 1.018bn • US: strong EGFR testing rates, 1L treatment rates for Mut+ve patients and increase in 1L maintenance use for squamous patients • EU: stabilization ahead of further reimbursement approvals for 1LMut+ indication; competitive challenges remain

134 CER=Constant Exchange Rates Inflammation/Autoimmune/Transplantation

1 IAT sales +13% YTD Sept 2013 IAT sales: CHF 2.468bn 2.5 +10% • Strong growth of Actemra/RoActemra and MabThera/Rituxan, CellCept stabilising 2.0 +7% Actemra/RoActemra 1.5 Sales: CHF 763m (+33%) +5% • Growth driven by monotherapy use; US

CHFbn 1.0 biggest growth contributor, good uptake of subcutaneous formulation in Japan

0.5 +27% CellCept Sales: CHF 681m (+1%) 0.0 • Patent expiry key EU countries end 2010 YTD 9 11 YTD 9 12 YTD 9 13

Japan International Europe US

135 1 CER=Constant Exchange Rates Tamiflu quarterly sales 2009 - 2013 Retail and Governments/Corporations

CHFm 1150 Retail Governments & Corporations 950 267 663 750

550 260 95

350 97 727 533 302 422 288 349 23 150 304 177 233 12 170 7 91 48 7 26 15 32 17 19 45 46 44 3 10 8 5 31 1 -50 -6 33 2 Q1 09 Q2 09 Q3 09 Q4 09 Q1 10 Q2 10 Q3 10 Q4 10 Q1 11 Q2 11 Q3 11 Q4 11 Q1 12 Q2 12 Q3 12 Q4 12 Q1 13 Q2 13 Q3 13

136 Roche Group development pipeline

Marketed products development programmes

Roche Pharma global development programmes

Roche Pharma research and early development

Genentech research and early development

Roche Group YTD Sept 2013 sales

Diagnostics

Foreign exchange rate information 137 YTD Sept 2013: Diagnostics Division CER growth By Region and Business Area (vs. 2012)

Global North America EMEA¹ RoW % CER % CER % CER % CER CHFm growth CHFm growth CHFm growth CHFm growth

Professional Diagnostics 4,227 7 851 4 1,900 3 1,476 14 Diabetes Care 1,781 -2 350 -11 1,076 1 355 -1 Molecular Diagnostics 1,188 2 421 4 462 0 305 3 Tissue Diagnostics 481 6 290 0 126 14 65 24

Diagnostics Division 7,677 4 1,912 0 3,564 3 2,201 10

CER=Constant Exchange Rates 138 ¹ Europe, Middle East and Africa Diagnostics Division quarterly sales and CER growth1

Q2 12 Q3 12 Q4 12 Q1 13 Q2 13 Q3 13 CHFm % CER CHFm % CER CHFm % CER CHFm % CER CHFm % CER CHFm % CER Professional 1,362 8 1,357 8 1,433 7 1,337 4 1,472 8 1,418 9 Diagnostics

Diabetes 696 3 577 -12 729 -1 539 -5 666 -4 576 3 Care

Molecular 395 1 395 -2 436 2 386 -3 411 6 391 4 Diagnostics

Tissue 158 16 153 10 173 7 157 7 165 4 159 8 Diagnostics

Dia Division 2,611 6 2,482 1 2,771 4 2,419 1 2,714 4 2,544 7

CER=Constant Exchange Rates 139 ¹ versus same period of prior year YTD Sept 2013: Diagnostics Division sales Growth driven by Professional Diagnostics

CHF 7,677 m CER sales growth

Diagnostics 4% 1,781 Diabetes Care 23% Division

Diabetes Care -2%

Professional Molecular Diagnostics 15% 1,188 Diagnostics 7%

Molecular 4,227 Diagnostics 2% 481 Tissue Diagnostics 6% Tissue 6% Professional Diagnostics 56% Diagnostics

140 CER=Constant Exchange Rates Professional Diagnostics Strong growth driven by immunoassays

2013 vs. 2012 CHFbn CER growth

5.0 +7%

4.0 -1% +3% 3.0 +4% 2.0

1.0 +13%

0.0 YTD 9 11 YTD 9 12 YTD 9 13 Immunoassay Clinical Chemistry POC products Other

141 CER=Constant Exchange Rates Diabetes Care Adapting to a challenging market environment

2013 vs. 2012 CHFbn CER growth

2.0 -2%

+3% 1.5

1.0 -3%

0.5

0.0 YTD 9 11 YTD 9 12 YTD 9 13 Blood Glucose Monitoring Insulin Delivery

142 CER=Constant Exchange Rates Molecular Diagnostics Growth driven by HPV and qPCR for life sciences

2013 vs. 2012 CHFbn CER growth

1.2 +2%

1.0 +2% +9% 0.8 +7% 0.6 +1% 0.4

0.2 0%

0.0 YTD 9 11 YTD 9 12 YTD 9 13 Virology Blood Screening qPCR & NAP Systems HPV & Microbiology Other 143 CER=Constant Exchange Rates Tissue Diagnostics Strong growth in EMEA¹ and APAC 2

2013 vs. 2012 CHFbn CER growth

0.5 +6% +91%

0.4 +15%

0.3

0.2 +3%

0.1

0.0 YTD 9 11 YTD 9 12 YTD 9 13 Advanced Staining Primary Staining Other

CER=Constant Exchange Rates 144 ¹ Europe, Middle East and Africa; 2 Asia Pacific 2013: Key planned product launches Professional Diagnostics

Product Description Region cobas 8100 pre- High throughput total lab automation system designed for EU  analytical series up to 1100 samples per hour and connectivity to SWA, Coagulation, Hematology and Urinalysis Elecsys Calcitonin Aids in the diagnosis and monitoring of medullary thyroid EU  immunoassay cancer

Elecsys proGRP Aids in the diagnosis of small cell lung cancer EU  immunoassay

Elecsys Cyclosporin Monitoring of immunosuppressive drug therapy in EU  & Tacrolimus transplant patients immunoassays

145 Planned launches may be delayed or not occur as a result of adverse regulatory decisions or other factors 2013: Key planned product launches Diabetes Care

Product Description Region

Accu-Chek Active Next-generation blood glucose monitoring system maltose EU  LCM independent strips

Accu-Chek Insight Next generation insulin delivery system combining an EU insulin pump and a blood glucose meter that functions as a pump remote control

146 Planned launches may be delayed or not occur as a result of adverse regulatory decisions or other factors 2013: Key planned product launches Molecular Diagnostics

Product Description Region

cobas EGFR test Companion diagnostic to Tyrosine Kinase Inhibitors / US  Tarceva for the detection of EGFR mutation in non-small cell lung cancer MPX 2.0 Next generation multiplex test for blood screening for HIV, US HCV and HBV CAP/CTM HCV 2.0 Next generation HCV viral load test US 

Seq Cap EZ* Reagent sets for targeted next generation sequencing WW 

GS FLX long Software for long-read targeted sequencing for DNA WW  amplicons* variant detection

* From Sequencing Solutions Unit 147 Planned launches may be delayed or not occur as a result of adverse regulatory decisions or other factors 2013: Key planned product launches Tissue Diagnostics

Product Description Region

ER test Estrogen receptor antibody (IHC) assay to support the US  diagnosis of breast cancer CINtec PLUS Immunocytochemistry assay used to screen women for EU Cytology cervical pre-cancer

148 Planned launches may be delayed or not occur as a result of adverse regulatory decisions or other factors Roche Group development pipeline

Marketed products development programmes

Roche Pharma global development programmes

Roche Pharma research and early development

Genentech research and early development

Roche Group YTD Sept 2013 sales

Diagnostics

Foreign exchange rate information 149 CHF / USD

Monthly averages 0.98

0.96 2013 2012 0.94

0.92

0.90 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

Year-To-Date averages 0.98

0.96

0.94 +1% 2013 +1% -1% 2012 0.92

0.90 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 150 CHF / USD

0.98

monthly avg 2012

0.96

monthly avg 2013 avg YTD 09 2012 0.94 avg full year 2012 -1% avg YTD 09 2013

0.92

0.90 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 151 CHF / EUR

Monthly averages 1.25 2013 1.23

1.21 2012

1.19 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

Year-To-Date averages 1.25

1.23 2013 +2% +2% +2% 1.21 2012 1.19 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 152 CHF / EUR

1.25

monthly avg 2013

1.23 avg YTD 09 2013

+2%

1.21 avg full year 2012 avg YTD 09 2012 monthly avg 2012

1.19 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 153 Average exchange rates

YTD Sep 13 YTD Sep 12 YTD Sep 13 vs. YTD Sep 12

USD 0.93 0.94

EUR 1.23 1.20

JPY 0.97 1.18

-20% -16% -12% -8% -4% 0% 4% 154 Exchange rate impact on sales growth In YTD Sep negative impact primarily from JPY partially offset by positive impact from EUR Development of average exchange rates versus prior year period CHF / EUR +1.6% +2.0% +2.2% CHF / USD +0.9% +0.8% -0.5% CHF / JPY -13.3% -15.8% -18.3%

Difference in CHF / CER -0.8%p -1.1 %p -2.5%p growth 5.9% 6.0% 5.1% 5.0% 3.9% 3.5% Sales growth CER CHF 2013 growth growth vs. 2012

Q1 HY YTD 9 FY 155 CER=Constant Exchange Rates Exchange rate impact on sales growth Negative impact from JPY and Latin American currencies

-1.9%

CER sales -0.7% -0.2% -0.2% growth -0.1% +0.5% 6.0% +0.1% YTD Sep 2013 CHF vs. sales YTD Sep 2012 growth 3.5% YTD Sep 2013 vs. YTD Sep 2012

CER JPY Lat-Am USD Other As-Pac Oth EUR CHF Europe 156 CER=Constant Exchange Rates Doing now what patients need next

157